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CHAPTER 1 
GENERAL INTRODUCTION 
Epidemiology of invasive candidiasis 
Candidiasis can be divided into superficial and invasive candidiasis. Superficial 
candidiasis strictly means lion the surfacell , The respiratory, urinary, and gastrointestinal 
tract are continuations of the body surface, thus, candidose of these sites should be 
regarded as superficial candidiasis. Candida lesions in all other sites are classified as 
systemic or invasive infections. Invasive forms of candidiasis may arise in one organ onlYI 
or as a truly disseminated candidiasis in which Candida is spread by the blood stream 
to invade multiple organs (1). 
Candida albicans is an opportunistic pathogen of the human gastrointestinal 
system that takes advantage of factors which decrease the normal host resistance to 
invade across the mucosa of the gastrointestinal tract (1, 2, 3). Haematogenous 
dissemination of C. albicans can lead to infection in virtually every organ or tissue of the 
human body (1). These infections are among the most important causes of morbidity and 
mortality among patients with cancer and other severely immunocompromised hosts (4). 
C. albicans is the most frequently isolated fungal pathogen (59.7%) followed by 
other Candida species (18.6%) including C. glabrata, C. tropicalis, C. krusei; and C. 
parapsi/osis (5, 6). This is in correlation to their virulence factors in terms of their capacity 
to adhere to both epithelial, and prosthetic surfaces (7), their proteolytic potential and the 
production of phospholipases (6). 
The frequency of invasive Candida infections has increased by 219 to 487% in 
U.S. teaching hospitals and by 75 to 370% in non-teaching hospitals during the past two 
decades (8, 9, 4, 10). Candida species are now the fourth most common organism 
recovered from blood of hospitalized patients (11). Although this increase may be due 
partly to increased awareness there is little doubt that a true increase in the number of 
Candida infections has occurred. Factors that have altered the epidemiology of candidal 
infections include prolonged mucosal damage due to chemotherapy or viral infections, 
increased use of broad~spectrum antibacterial agents, central vein catheterization, and 
increased periods of prolonged neutropenia consequent to the use of intensive 
chemotherapeutic regimens (8, 12). 
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Diagnosing invasive candidiasis. 
The problem 
Despite recognition of the above mentioned increase in Candida infections, 
diagnosis of invasive candidiasis remains difficult. Unfortunately, the clinical signs and 
symptoms associated with invasive candidiasis are non-specific and not helpful in 
distinguishing between bacterial or candidal infections (13). 
Other sources of difficulties in diagnosing invasive candidiasis arise from the 
problem of distinguishing clinically insignificant yeast colonization from invasive 
candidiasis with regard to the risk of antifungal chemotherapy. The drugs available for 
treatment of invasive candidiasis carry either high risk of host toxicity (Amphotericin B), 
a high probability that drug resistance will develop (fluconazole) or uncertain therapeutic 
efficacy (azole antifungals). 
The diagnosis of invasive candidiasis partly depends on culture andlor histological 
evidence from appropriately collected blood andlortissue biopsies of normal steri Ie body 
cavities (1). On the other hand, non-culture techniques are helpful in confirming and 
establishing the diagnosis invasive candidiasis which include detection of anti-Candida 
antibodies, antigens and metabolic products of Candida, and, recently, the detection of 
Candida species-specific DNA or RNA sequences in blood or other body fluids (13, 14, 
15). The non-culture-dependent diagnostic approaches will be discussed separately. 
Anti-Candida antibodies 
For the detection of specific antibodies several serologic tests have been 
developed; whole cell agglutination (16), latex agglutination (17), 
counterimmunoelectrophoresis (CIE) (18), indirect immunofluorescence (19), passive 
haemagglutination (20), radioimmunoassay (RIA) and enzyme immunoassay (ErA) (21). 
Several Candida antigenic determinants have been used in such tests. They include 
polysaccharides (cell wall antigens, mannan), proteins (cytoplasmic extracts) and 
glycoproteins (antigenic components released by Candida cells into their growth medium) 
(21-25). 
There are two major problems that undermine the clinical use of anti-Candida 
antibody assays. Due to the ubiquity of C. albicans as a human commensal anti-Candida 
antibodies are commonly present within patients and cause diagnostically "false-positive" 
results. In contrast the lack of an immuneresponse within immunocompromised patients 
results in diagnostically "false-negative" reactions (26). Alternatively, antibody production 
may occur so late in the course of the disease that it lacks diagnostic value, in clinical 
practice. 
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Immunodominant antigens have been adapted for use in immunoassays to increase 
specificity of the antibody detection assays, based on the assumption that the host is 
exposed to these antigens solely in invasive candidiasis (26). Several immunodominant 
antigens of C. albicans of similar molecular weight, correlated to invasive infection, have 
been described (27). The two major immunodominant antigens of interest for the 
development of antibody detection assays, are the 47 kDa breakdown product of a 90 
kDa heatshock protein (28) and the 45 kDa enzyme enolase (29, 30). 
None of the above mentioned tests have been commercialized or standardized 
internationally which makes comparison between various studies using these methods 
difficult. 
Structural antigens 
Several immunologic and chromatographic principles have been employed to 
detect cell wall and cytoplasmic antigens of c. albicans. At least three assays for 
detection of different Candida antigens have been made available by commercial 
companies. These assays include a latex agglutination (LA) assay for an undefined heat-
labile antigen (CAND-Tec, Ramco, Houston) (31), an enzyme immunoassay for Candida 
enolase (Becton Dickinson, Microbiology Systems, Baltimore) (32) and tests for the 
detection of cell wall mann an (LA-Candida Antigen Detection System , Immuno-
Mycologies, Norman, OK; Pastorex Candida, Diagnostics Pasteur, Marnes-Ia-Coquette, 
France; Hybritech EIA, San Diego) (33-35) (Table 1). 
Table 1. Antigen detection tests for the diagnosis of invasive candidiasis. 
antigen/test patient percentage ('!oj references 
population sensitivity specificity 
heat-labile'/LA Mixed 21-91 29-98 [36-44J 
enolase/EIA Neutropenic 85 96 [32J 
mannan/lA or Mixed 47-66 89-100 [33, 35, 45-48J 
EIA 
I at a cutoff point of ~ 1:4 
LA = latex agglutination; EIA = enzyme immunoassay 
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The CAND-Tec is currently the most widely available and used assay. The test 
however, is rather insensitive and antigen tends to be detectable only late in the disease. 
Also, the wide range of antigen titers detected by the CAND-Tec assay among healthy 
donors and patients reduces the applicability of the test in a clinical laboratory (Table 1). 
The Becton Dickinson kit for enolase has already been withdrawn from the market. 
Detection of mannan is troublesome since mann an is eliminated rapidly from the 
bloodstream and circulates at very low concentrations as soluble immune complexes 
which have to be dissociated before detection. 
Metabolic antigens 
Assays have been developed for the detection of circulating Candida sugar 
metabolites such as mannose and arabinitol (49) which are both markers for disseminated 
candidiasis (50). Both can be quantified by gas liquid chromatography (15). 
Much effort has been given into the detection of arabinitol. The enantio-selective 
measurement of D-arabinitol in human serum was originally performed by microbiologic-
gas chromatographic (GC) (51) or enzymatic-GC techniques (52). Although these 
techniques are specific for D-arabinitol they are expensive, technically demanding and 
therefore not useful for routine diagnostic laboratoria. The use of an automated 
quantitative enzymatic assay for the detection of serum D-arabinitol using the enzyme D-
arabinitol dehydrogenase, seems promising (53-55). However, arabinitol is cleared by the 
kidneys so that the normal range of serum concentration has to be adjusted in patients 
with renal insufficiency. Subsequently, D-arabinitol/creatinine ratios were used to avoid 
false positive results due to renal impairment (56, 57). 
Recently, Walsh et al. (58) established in an experimental rabbit model of 
disseminated candidiasis a direct correlation between D-arabinitollcreatinine ratio's and 
tissue concentrations of C. albicans. They also suggested the use of the D-
arabinitol/creatinine ratios in monitoring the efficacy of antifungal therapy. The diagnostic 
and prognostic validity of this assay has still to be determined in patients. 
DNA detection 
The specific diagnosis of invasive candidiasis depends primarily on the repeated 
recovery of the organism from blood specimens or normally sterile tissue sites. 
Unfortunately, it is apparent that Candida species are recovered from only 15-50% of 
patients with invasive candidiasis and cultures become positive only at a late stage of the 
disease (13). Although the lysis-centrifugation blood culture system increases the 
detection rate it is still not adequate (59). The detection of fungal species-specific DNA 
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sequences, as a non~culture technique, has the potential to be sensitive, specific, and 
rapid. Most work in this area has focused on the epidemiologic typing of Candida species 
(60, 61); however, application of the polymerase chain reaction (PCR) to the detection 
of Candida species in clinical specimens has been recently described (Table 2) (13). 
Table 2. Yeast DNA detection using different genes, specimens and methods. 
detection gene target specimens ref. 
threshold 
(CFU/ml) 
100 cytochrome P450LIA1 Candida spp. U, 5, W, B [62J 
30 E03 DNA fragment C. albicans U, B [63, 64J 
100 ribosomal RNA gene yeast DNA B [65J 
15 ribosomal RNA gene yeast DNA B [66, 67] 
100 Candida actin gene Candida spp. B [68J 
100 ribosomal RNA gene yeast DNA PBS [69J 
1000 C. albicans HSP 90 C. albicans sw, U, P, [70J 
pus, 8, se 
• U = urine, S =sputum, W=wound fluid, 8=blood, 5W= swabs, P=peritoneal fluid, se= serum. 
PCR may be used to simultaneously detect and identify Candida species in clinical 
specimens which is another advantage over blood culture. Several techniques have been 
described for the isolation of yeast DNA from blood, but large volumes of blood (5 011) 
have never been used. Generally, the techniques described in Table 2 are still too 
complex to be used in a routine setting. Further simplification is necessary while 
maintaining or preferably improving the detection limit of about 100 cellslml blood. 
Although several studies have used patient material for evaluation (often culture 
positive) there is as yet no large clinical study in which PCR is compared with blood 
culture. The diagnostic or prognostic usefulness has, therefore, still to be established in 
a well designed patient study. 
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Aim of the present study. 
It is evident that accurate diagnosis of disseminated candidiasis is fraught with 
difficulties. The aim of this thesis was to investigate whether accurate diagnostic assays 
could be developed, in combination with their use in monitoring the progression of 
infection and response to treatment. In the first place we evaluated the use of more 
specific and sensitive antibody detection systems. As discussed in the diagnostic section, 
the detection of antibodies directed against C. albicans is limited by false positive and 
false negative results. In order to overcome these problems, we used purified cytoplasmic 
antigens (Chapter 2) and an immunodominant 45 kDa enolase antigen (Chapter 3), to 
determine specific antibodies using sensitive determination techniques such as ELISA. The 
diagnostic contribution made by these assays was investigated in different groups of 
patients. Initially, to determine the prevalence of these antibodies in a normal population 
a group of healthy donors was investigated. Simultaneously, a group of patients colonized 
by C. albicans but without signs of an invasive Candida infection, and a group of patients 
with a proven invasive candidiasis was investigated. Separate evaluations were made for 
immunocompetent and immunodeficient patient groups. Patients from whom consecutive 
serum samples were available were used to study the prognostic value of these assays in 
comparison to existing serologic assays (Chapter 4). 
The detection of fungal species-specific DNA by PCR was evaluated for its 
diagnostic usefulness (Chapter 5). We also monitored the results of PCR on blood 
samples from neutropenic mice with invasive candidiasis treated with various 
concentration of liposomal Amphotericin B (Chapter 6). 
Finally, we evaluated the contribution of antibodies directed against a crude 
antigen and the immunodominant enolase antigen, in protection against a Candida 
infection in an experimental mouse model (Chapter 7). To gain insight into the protective 
effect of anti-enolase antibodies, the opsonic capacity with anti-enolase antibody for C. 
albicans was investigated using macrophage monolayers. 
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ABSTRACT 
In several studies it was shown that cytoplasmic antigens of Candida albicans 
were more frequently found in the sera of patients with invasive candidiasis, than in 
the sera of patients with superficial candidiasis. In this study, therefore, it was 
examined whether the specificity and the sensitivity, of a counter-
immunoelectrophoresis technique (CIE), used in our laboratory, could be improved, 
by using cytoplasmic antigens depleted of mann an residues, and also by staining the 
precipitated complexes. Three successive serum samples, if possible, were collected 
from 44 patients with major surgical problems (but without haematological 
malignancies) of which 30 had invasive candidiasis and 14 superficial candidiasis. The 
CIE using the cytoplasmic antigen depleted of mann an was better in discriminating 
between invasive and superficial candidiasis. The specificity of the CIE increased from 
28.6 to 78.6% when cytoplasmic antigens depleted of mannan were used, while the 
sensitivity slightly decreased from 80 to 70%. Diagnostic accuracy did not improve 
with addition of an antigen detection assay (Cand-Tec). 
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INTRODUCTION 
The frequency of invasive candidiasis as a major cause of morbidity and 
mortality among hospitalized patients has increased. An antemortem diagnosis of 
invasive candidiasis is very difficult because there is no specific clinical picture. 
Although isolation of Candida spp. from clinical specimens and serodiagnostic tests 
for antigen and antibody detection may help in diagnosis, the following problems are 
inherent. In 56% of the cases, blood cultures of patients with autopsy-proven 
disseminated candidiasis, are negative for Candida albicans (20). Tests for the 
detection of circulating Candida antigens lack sensitivity and have been controversial 
(3, 4, 12, 13, 17, 21), while antibody detection systems mainly detect antibodies 
against Candida cell wall antigens which are ubiquitous in sera of patients with 
systemic candidiasis as well as in the sera of patients with superficial candidiasis (11, 
15). To obtain a more specific test, investigators have evaluated the usefulness of 
measuring antibodies to cytoplasmic antigens (9, 23, 24, 25). The hypothesis behind 
these studies was that cytoplasmic antigens are only exposed during invasive infection 
and are therefore predictive and specific for invasive candidiasis (23, 25). For instance, 
Syverson et al. (24) and Van mali et al. (26) used a crossed immunoelectrophoresis 
technique (XIE) with concanavalin A intermediate gel and a double immunodiffussion 
assay to evaluate the diagnostic usefulness of the antibody response to cytoplasmic 
antigens. The XIE was superior over the double immunodiffusion assay. Despite its 
high specificity, the test was not recommended for a routine seUing because of the 
complexity of the technique. 
In the present study, we evaluated the antibody response against cytoplasmic 
antigens from C. albicans in the presence and absence of mannan residues in the sera 
of surgical patients with either invasive or superficial candidiasis. To evaluate whether 
combinations of antibody detection and antigen detection assays could improve 
diagnostic accuracy, antigen titers in the same sera were determined by the Cand-Tec 
test. 
MATERIALS AND METHODS. 
Patient sera. Sera from patients included in this study were collected between october 
1982 and january 1991. The majority of the patients underwent major abdominal surgery. 
None of the patients in this study had haematological malignancies or had received treatment 
with corticosteroids, immunosuppressive Of cytostatic drugs or total body irradiation. On the 
basis of clinical findings and culture results these surgical patients were subdivided into two 
groups according to earlier·defined criteria. Group I consisted of 30 patients with proven 
invasive candidiasis. The criteria for this diagnosis were based on obtaining positive Candida 
albicans cultures from tissue biopsy, needle aspiration of normally sterile body cavities, or at 
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autopsy. One or more positive blood cultures was not regarded adequate to classify a patient 
as having invasive candidiasis. Group II consisted of 14 patients with a superficial c. albicans 
infection. Superficial candidiasis was determined by more than one positive C. albicans 
culture which had been isolated from different parts of the gastrointestinal tract in the absence 
of visible lesions. 
Serological tests were done with fresh or fresh-frozen (-80°C) sera. In this study, 3 serum 
samples per patient, if available, were included for serological evaluation. The sera were 
obtained, at weekly intervals. The first sample was defined as the serum obtained at the time 
of the first microbiological evidence of invasive candidiasis. 
Preparation of the cytoplasmic antigen with mannan residues. The cytoplasmic antigen 
was prepared by growing C. albicans (CBS 5982 serotype A, Centraal bureau voor 
schimmelcultures, Delft, The Netherlands) overnight at 37'C in minimal medium (11.7 gil 
Yeast Carbon Base (Difco laboratories, Detroit, Michigan USA), 10 gil D-Glucose, 20 gil 
Bactopeptone (Difco)). Cells were harvested by centrifugation and washed twice in distilled 
water. The final pellet was dissolved in 42 ml icecold ammonium carbonate (20mM) followed 
by disruption with glassbeads (2mm) for 15 min in a Braunshaker (Kobold, FRG) under 
continuous CO2 cooling. Cell walls were spun down at 5000 x g at 4°C for 45 min--(Beckman--
JA20), and the supernatant was further centrifuged at 40.000 x g at 4'C for 30 min (Beckman 
JA20). The final supernatant was lyophilized and stored at -20'C (10), and will be referred to 
as M( +) antigen. 
Preparation of the cytoplasmic antigen depleted of mannan. The cytoplasmic antigen 
depleted of mannan was prepared from the lyophilized M( +) antigen by removing mannan 
determinants using af{jnity chromatography on concanavalin A-Sepharose 4B (Pharmacia LKB, 
Uppsala, Sweden) according to the method of Ellsworth et al. (6). The eluent, containing the 
unbound material was concentrated by ultrafiltration (Amicon PM10 filter, Pharmacia), stored 
at 4'C, and will be referred to as the M(-) antigen. Before applying the M(-) antigen in the CIE 
it was examined for remaining mannan, by using a commercial latex kit (Pasteur diagnostica, 
France) and by using XIE. 
Immunoelectrophoresis. Counterimmunoelectrophoresis was performed according to the 
method of Marier (16). Precipitating antibodies were scored before and after staining with 
Coomassie Brilliant Blue R-2S0 (Sigma Chemical Co., St. louis, Mo.). Results were designated 
as CIE and ClE-stained, respectively. Antibody titers of 1:2 and 1:4 or higher, using the M( +) 
antigen, were regarded as positive in the ClE and CIE-stained, respectively. Antibody titers of 
1:1 and 1:2 or higher, using the M(-) antigen were regarded as positive in the CIE and CIE-
stained, respectively. 
Characterization of the M( +) antigen and the M(-) antigen by XIE. The method applied 
was originally evaluated by Axelsen (1). Briefly, glassplates (5 x 5 cm.) with 1 % agarose 
(Sigma) in Barbital buffer (pH 8.6, /I~0.02) were used. The M(+) antigen or M(-) antigen was 
electrophoresed (10 V cm-l ) in the first dimension. The run in the second dimension against a 
hyperimmune rabbit serum (5 /llIcm' DAKO) was performed for 18 h at 2 Vern". After 
electrophoresis gels were washed first in 0.9% NaCI overnight then in distilled water for lh. 
Finally the gels were bound to agarose gelbond film (Bio-Rad Laboratories, Richmond, CAl 
and then stained with Coomassie Brilliant Blue R-250 (Sigma). 
For comparison of the CIE using M(-) antigen (M(-)CIE) with the ClE using M(+) antigen 
(M( + )CIE), antigen concentrations were equalized by titration in such a way that the areas 
under six of the same precipitins of both antigens were the same when electrophoresed 
against a rabbit hyperimmune serum (5 /II/em' DAKO) in the XIE. This titration actually 
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resulted in a concentration of 100 pg/ml of protein for both the M(+) and M(-) antigen, as 
used in the particular CIE. 
Antigen detection assay. Titers of circulating antigens were determined by the Cand-Tec 
assay (Rameo laboratories Inc., Houston, Tex.) (2, 5), according to the directions of the 
manufacturer. A serum dilution of 1:4 or higher was regarded as a positive titer. 
Statistical analysis. Correlations between the three serum samples obtained from each 
patient were assessed using the Intradass correlation coefficients ('I). The capacity to 
discriminate between invasive and superficial candidiasis was evaluated by the Mann Whitney 
test (MW). Logistic regression was used as multivariable analysis, to evaluate various 
serological assays simultaneously, with regard to their discriminating capacities. 
RESULTS 
Characterization of the M( +) and M(-) antigen. Before applying the M(-) antigen 
in the CIE it was examined for remaining mannan by crossed immunoelectrophoresis 
(XIE) (1). When M( +) antigen was electrophoresed against a patient's serum in XIE, 
different precipitins were observed (Fig. 1A). As indicated by the arrow very strong but 
indistinct precipitins could be observed, but also very sharp but less intens precipitins. 
By tandem XIE the large precipitin appeared to be identical to a purified 
immunodominant antigen which in our hands had enolase activity (data not shown). 
When M(-) antigen was used in the XIE the strong but indistinct precipitins due to 
mannan residues disappeared (Fig. 1 B) (25). Also, with the commercial mann an kit 
(Pasteur diagnostica, France) the M(-) antigen did not react. However, in order to 
correlate antibody titers obtained by the CIE using M(-) antigen (M(-)CIE) with the CIE 
using M( +) antigen (M( + )CIE), concentralions of antigens other than mann an, were 
equalized by titralion in such a way that the areas under six of the same precipitins of 
both antigens were the same when electrophoresed against a rabbit hyperimmune 
serum (5 J11/cm' DAKO) in the XIE. This titration aClually resulted in equal protein 
concentrations of 100 J1g1ml for both the M( +) and M(-) antigen, as used in the 
particular CIE. 
Discriminative capacity of the Cand-Tec, M(+)CIE, and M(+)CIE-stained. The 
M( + )CIE results showed that for patienls with invasive candidiasis, there was an 
increase in the percentage of positive antibody titers in the three serum samples 
examined (Table 1). For patients with a superficial Candida infection, the titers were 
either stable (without staining), or decreased (with staining), with time. Antigen titers, 
measured by Cand-Tec, however, decreased from 50 to 36% in the same sera from 
patients with invasive candidiasis, or remained stable in the sera from patients with 
superficial candidiasis. 
Despite these increases in CIE titers as determined by M( + )CIE (for patients from 
whom three serum samples were available, n ~ 13), slatistical analysis on the sera from 
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all patients (n ~ 30) showed no significant differences with time. The titers for serum 
samples 1, 2, and 3 of each patient appeared strongly correlated without (r,~0.76), 
and with (r;~0.78) staining. 
A B 
Figure 1. XIE demonstrating antibodies against the M(+) (A) and M(-) (B) antigens. Antibodies 
against mannan are indicated by arrows. 
Table 1. Percentage of positive titers by M( +)CJE for patients with invasive (group I, n= 13) or 
superficial (group II, n = 6) candidiasis from whom three serum samples were available 
Serum % of gositive titers b:i M( + KIP-
sample Without staining With staining 
no. I II I II 
77.0 60.0 46.2 80.0 
2 92.4 60.0 61.6 60.0 
3 92.3 60.0 84.7 20.0 
a Cutoff values for positive titers were;?: 2 without staining and;;:: 4 with staining. 
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Therefore, to evaluate the capacity of the ClE test to discriminate between 
invasive and superficial candidiasis, the mean titers of serum samples 1, 2, and 3 were 
used, after logarithmical transformation. Figure 2 shows the distribution of the mean 
logarithm(titer+ 1) obtained for each patient. 
On the basis of statistical analysis, it was observed that the M( + )CIE test without 
staining could not discriminate between groups I and II (MW P~0.09). However, 
significant differences were found between groups I and II (p~0.04) when the gels 
were stained before scoring. Generally higher values were obtained for group I. At a 
cutoff value of 1:4 M( + )CIE-stained had a sensitivity of 66.7 and a specificity of 
57.2%. The Cand-Tec assay on the other hand did not discriminate between the two 
patient groups (P ~ 0.12). 
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Figure 2. Distribution of the mean logarithm(titer + 1) obtained for each patient with invasive 
(group I) or superficial (group II) candidiasis . • , M( + )CIE without staining; ., M( + )CIE with 
staining; /1.., Cand~Tec. 
Discriminating capacities of the M(-)CIE and the M(-)CIE-stained. By M(-) CIE, 
titers were lower (or absent) than those by M( + )CIE for all serum samples from 
patients with either invasive or superficial candidiasis (Table 2). 
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Table 2. Percentage of patients with invasive (group I, n=30) or superficial (group II, n= 14) 
candidiasis with the indicated mean titer value for each test. 
% of gatients with indicated titer in groue: 
Test I II 
0-1 2 24 0-1 2 24 
M(+)CIE 
Without staining 6.7 30.0 63.3 0.0 50.0 50.0 
With staining 3.3 26.6 70.0 0.0 42.9 57.1 
M(-)CIE 
Without staining 56.7 20.0 23.3 85.7 14.3 0.0 
With staining 30.0 40.0 30.0 35.7 57.1 7.1 
Table 3. Percentage of positive titers by M(-)CIE for patients with invasive (group I, n ~ 12) or 
superficial (group fI, n = 6) candidiasis from whom three serum samples were available 
Serum % of gositive titers b¥ M{-}CIE 
sample Without staining With staining 
no. I II I II 
50.0 20.0 50.0 20.0 
2 66.7 20.0 83.4 20.0 
3 66.7 20.0 66.6 20.0 
for the patients from whom three serum samples were available (n ~ 12), an 
increase in positive titers between the first and the second serum was observed, by 
M(-)CIE with and without staining (Table 3). However, the mean values of titers for 
serum samples 1, 2, and 3 for all patients did not significantly differ. Again, the serum 
titers were transformed as mentioned before and are depicted in fig. 3. By statistical 
analysis, the mean levels of titers obtained by M(-)CIE without staining were 
significantly higher for invasive candidiasis than for superficial candidiasis, irrespective 
of a chosen cutoff value (P ~0.005). At a cutoff value for a positive titer of 1: 1, the test 
had a sensitivity of 70% and a specificity of 78.6%. M(-)CIE with staining, on the 
other hand, could not discriminate between groups I and II (p~0.06). from the results 
given in Table 4, there is an actual increase in specificity of the test, by removing 
mannan, from 28.6 to 78.6% or from 57.2 to 85.7% by CIE without and with staining. 
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Figure 3. Distribution of the mean !og(titer + 1) obtained for each patient with invasive 
(group I) or superficial (group II) candidiasis. " M(-)C/f without staining; ., M(-)C/f with 
staining. 
Table 4. Sensitivity and specificity of the different tests determined at a chosen cutoff value 
by using the mean log(titer + T) value for groups I and /I 
Test Cutoff Sensitivity Specificity P value;! 
value (%) (%) 
Cand-Tec 24 26.7 85.7 0.46 
M(+)CIE 
Vv'ithout staining 22 80.0 28.6 0.43 
With staining 24 66.7 57.2 0.19 
M(-)CIE 
vVithout staining 21 70.0 78.6 0.0037 
With staining 22 50.0 85.7 0.0013 
The P value was determined by the Fisher exact test by comparing the percentages of 
patients with a titer above cutoff levels for groups I and II. 
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DISCUSSION 
It is known, from literature data and from our own investigations that several 
cytoplasmic antigens, including the 47 kDa antigen of C. albicans, are the most 
frequently found inducers of antibodies in the sera of patients with invasive 
candidiasis (18, 22, 27). Antibodies directed against the 47 kDa antigen, in addition to 
other cytoplasmic antigens, were either rare in uninfected controls or, were 
infrequently found in superficially infected patients. Therefore, these cytoplasmic 
antigens could serve as the basis of a reliable diagnostic test. The purpose of this study 
was to develop a serological procedure suitable for a routine microbiological 
laboratory. In this study, it is found that 30.0% of the patients (n~9), with invasive 
candidiasis gave a negative response to the M(-)CIE, whereas only one patient did not 
respond in the M( + )CIE. In contrast, 78.6% of the patients with superficial candidiasis 
(n ~ 11) responded negatively to the M(-)CIE but all responded to the M( + )CIE. These 
results confirm the findings of Matthews et al. (18) who found that, a negative 
response in an antibody test may be due to the small number of antigens applied and 
therefore, not always due to the inability of some patients to produce antibodies (19). 
However, in accordance with Jones et al. (11), we found that the use of more antigens 
including mannan antigens, lead to low specificities in antibody detection assays. 
It was further shown that during the first two weeks after the first clinical signs of 
invasive candidiasis, titers increased, leading to higher sensitivities of the test, 
confirming the findings of Kostiala et al. (14). Increasing titers over time in our data, 
however, were not significant because of the large number of patients for whom only 
one or two successive serum samples were available. 
Despite the fact that the M(-)CIE had a diagnostic value, the test has only 
moderate sensitivity. This is because nine patients (30%), with invasive candidiasis, 
did not have an antibody response against the M(-) antigen. From six of these nine 
patients, only one or two serum samples were available, because of early death within 
6 to 16 days after the clinical onset of disease. From the 21 patients who did produce 
antibodies against M(-) antigen, 8 died despite antibody production. However, 13 .of 
the 14 patients who died produced antibodies against the M( +) antigen. Perhaps these 
patients produced antibodies against mann an initially but were not able or did not 
have the time, to develop an antibody response to the M(-) antigen including the 47 
kDa antigen. Matthews has suggested that antibodies against 47 kDa antigen might be 
protective (18). 
Staining of the precipitated complexes led to a general increase in the sensitivity 
of the test for both groups I and II. In order to maintain the discriminative capacity of 
the test, higher cutoff values were needed. Eventually, because of this procedure the 
sensitivity of the test with staining decreased in comparison with the test without 
staining. By removing mann an residues from the cytoplasmic antigen applied, the 
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specificity of the CIE increased from 28.6 to 78.6%. Fisher et al. (7) found a specificity 
of 90% and a sensitivity of 92% for their EIA with the commercially supplied 
Hollister-Stier sonicate antigen of C. albicans. Probably the differences are due to the 
fact that they used healthy volunteers or patients without signs of a Candida infection 
as a control group to calculate sensitivites and specificities. In the same study, it was 
claimed that a combination of both antibody and antigen detection assays 
considerably improved diagnostic accuracy. logistic regression analysis of our data did 
not show any improvement when the antigen and antibody results were combined. 
The data obtained with the Cand-Tec test were not as favourable as claimed in 
other studies (5, 8). Discrepancies again may be due to different selection criteria used 
for determining invasive candidiasisl since our criteria were more restrictive. Since the 
presence of antigens in patient sera induce the synthesis of antibodies, a decrease in 
antigen titers could therefore be explained by the formation of antigen antibody 
complexes or by renal excretion, suggesting, that antigen titers are probably best 
determined in the early onset of invasive candidiasis. 
In conclusion, we believe that for patients with surgical problems without 
haematological malignancies, the M(-)CIE can assist the clinician in the diagnosis of 
invasive candidiasis at an early stage of infection. Further study is obviously needed to 
assess the use of the M(-)CIE in immunocompromised patients. 
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ABSTRACT 
An irnrnunodominant antigen with enolase enzyme activity was purified and used 
for the development of an assay to detect antibodies directed against this antigen in sera 
of patients with either invasive candidiasis or Candida colonization. The enzyme-linked 
immunosorbent assay established with the Candida enolase antigen was able to 
discriminate significantly between invasive candidiasis and colonization in both 
immunocompetent and immunodeficient groups of patients. The test had a sensitivity of 
50% and a specificity of 86% in the immunocompetent patient group. In the 
immunodeficient patient group a sensitivity of 53% and a specificity of 78% were 
established. Antibody levels determined by a counterimmunoelectrophoresis assay with 
the same set of sera resulted in a better sensitivity for sera from the immunocompetent 
patient group but a lower specificity, i.e. 80% and 29% respectively. The counter-
immunoelectrophoresis assay of sera from the immunodeficient patient group was not 
able to discriminate significantly between invasive candidiasis and colonization. With the 
use of more serum samples per patient, the sensitivity of the antibody detection assays 
increased while the specificity was maintained. The increase, however, was statistically 
not significant. Combining the results of the antibody assays with antigen titers obtained 
by the Cand-Tec assay did not improve the predictive value with respect to invasive 
candidiasis, as determined by multivariance regression analysis. Furthermore, it was 
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demonstrated by performance of Western blots (immunoblots) that sera of patients as well 
as a rabbit antiserum cross-reacted with the Candida enolase and baker's yeast enolase 
enzyme. However, by tandem crossed immunoelectrophoresis it was demonstrated that 
the antibodies were directed towards different epitopes of the antigen. 
INTRODUCTION 
The use of antibacterial, immunosuppressive, and cytotoxic drugs increases the 
incidence of lethal invasive candidiasis in hospitalized patients (13). Despite many 
attempts to develop reliable serological tests, the laboratory diagnosis of deep-seated 
Candida infection still remains a problem (3, 11). Until now, antibody detection tests 
with crude antigens have produced suboptimal sensitivities andlor specificities (11). 
However, the detection of antibodies directed against specific antigens seems promising. 
Matthews et al. (17) demonstrated that the presence of antibodies against an 
immunodominant antigen of Candida albicans with a molecular mass of 47 kDa 
correlated with invasive infection. Since cytoplasmic antigens are released during invasive 
infection, it is conceivable that cytoplasmic antigens applied in an antibody detection 
assay could discriminate between invasive candidiasis and colonization. Recently, Zoller 
et al. (23) reported in a mixed immunocompromised and immunocompetent patient 
population a sensitivity and a specificity of 81.5 and 96.4%, respectively, for an antibody 
detection assay that made use of the partially purified 47 kDa antigen. 
In the present study, we purified an immunodominant antigen of C. albicans and 
used it to develop an enzyme-linked immunosorbent assay (ELISA) which discriminates 
positively between invasive candidiasis and colonization. Since several contradictory 
results have been published concerning the presence or absence of enolase activity in the 
immunodominant antigen, we also analyzed the purified antigen by Western blot 
(immunoblot) and tandem crossed immunoelectrophoresis (XIE) and subsequently tested 
it for enolase activity. 
To determine whether the kinetics of the antibody response is more importantthan 
the antibody titer itself, three successive serum samples from each patient, when 
available, were included for serological evaluation. The results obtained by the ELISA 
were compared to titers of antibodies directed against a cytoplasmic antigen-containing 
mannan [M( +) antigen] and to antibody titers directed against a cytoplasmic antigen 
depleted of mann an and glycoproteins [M(-) antigen] as determined by a 
counterimmunoelectrophoresis (CIE) technique. Besides antibody detection, the same 
serum samples were analyzed for circulating antigens by the Cand-Tec assay. 
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MATERIALS AND METHODS 
SDS·PAGE and immunoblolting. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS·PAGE) and immunoblotting were performed as described previously (19). 
In brief, proteins were separated electrophoretically in a discontinuous system as described by 
laemmli (15). The electrophoresis system consisted of a 10% running gel and a 4% stacking gel, 
and the proteins were subsequently transferred to a polyvinyldifluoride membrane (lmmobulon-P; 
Millipore) by the method of Towbin et al.(20). For immunoblotting, diluted rabbit antiserum 
raised against a crude antigen prepared from C. albicans CBS 5982 serotype A (Centraal Bureau 
vaor Schimmelcultures, Delft, the Netherlands) and patient sera were used. Blots {bands} were 
developed with alkaline phosphatase·conjugated anti·rabbit immunoglobulin G (lgG) or anti· 
human IgG, respectively, by using 5-bromo,4 chloro-3-indol phosphate (Sigma Chemical Co., St. 
Louis, MO.) and nitroblue tetrazolium (Sigma) as substrate. 
Purification of the immunodominant Candida antigen. For purification procedures C. 
albicans CBS 5982 serotype A was grown for 48 h at 37'C in 2 liters of minimal medium (11.7 
g of yeast Carbon base per liter, 10 g of D·Glucose per liter, 20 g of Bacto Pepton [Difco 
laboratories, Detroit, Mich] per liter). Cells were harvested by centrifugation and were washed 
twice in distilled water. The final pellet was dissolved in 42 ml ice-cold distilled water and was 
then disrupted with glassbeads (diameter,2 mOl) for 15 min in a Braun shaker (B. Braun, 
Melsungen, Germany) under continuous CO2 cooling. The suspension was spun down at 40,000 
x g at 4°C for 20 min. Supernatants were stored overnight at -80°C and after being thawed were 
centrifuged at 40,000 x g for 20 min at 4°c' Supernatants were brought to 50% saturation by 
adding a saturated solution of (NH.j)2S04' Further saturation to 67% was obtained by adding solid 
(NH4),SO, to the supernatant. The solution was then centrifuged at 40,000 x g at 20'C for 20 
min, and solid (NH4)2S0.j was added to the supernatant untiil00% saturation was accomplished. 
After 20 min at room temperature, the solution was further centrifuged at 40,000 x g at 20°C for 
20 min. The pellet was resuspended in a Tris buffer (0.067 M; pH 7.5) and desalted by using a 
Sephadex G25 Column (Pharmacia lKB, Uppsala, Sweden). The protein-containing fraction was 
further purified by a fast·performance liquid chromatography (FPlC) on a Highload Q·Sepharose 
high performance column (FPlC HQSHP; Pharmacia) by using a 0 to 10% gradient of 2 M NaCl 
in a 0.067 M Tris buffer (pH 7.5). Gradients were created using 325 ml (1 to 3%) or 150 ml (3 
to 10%) of 2 M NaCi at a flow rate of 4 mllmin. Aliquots of each fraction were analyzed by SDS· 
PAGE, and the enolase activity in each fraction was determined. Samples containing enolase 
activity were pooled and exchanged with a 20 mM piperazine buffer (pH 6.0) on a Sephadex 
G25 column. The pooled fraction was loaded on a FPlC Mono P column (H 5/20; Pharmacia), 
and proteins were separated by a linear gradient from pH 6 to pH 4.5 in polybuffer. 
Fractions containing enolase activity were analyzed by 50S-PAGE, pooled and exchanged 
with a concanavalin A starting buffer (0.02 M Tris, 0.1 M NaCi, 1 mM CaCI" 1 mM MnCl, [pH 
7.4]) before they were applied to the concanvaline A-5epharose column (Pharmacia) in order to 
remove mannan by the method of Ellsworth et al. (5). Removal of mannan was confirmed by a 
negative result in the mannan kit of Pasteur (Diagnostics Pasteur, Marnes-Ia-Coquette, France). 
Finally, the immunodominant antigen containing enolase activity was stored at -80°C in a 0.01 
M Tris buffer (pH 7.5 ). 
Enolase activity. During the purification procedure, fractions were analyzed for enolase 
activity by the method of McAliistor and Holland (18). 
ELISA. Optimal concentrations of the antigen, sera, and conjugate were predetermined 
by checkerboard titrations with known positive and negative sera obtained by Western blotting. 
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Highly activated polystyrene microtiter plates (Nunc immunoplate Maxisorp F96) were coated 
with 1.5 flg per well of Candida antigen in 50 fll of coating buffer (0.13 M sodium carbonate and 
0.03 M hydrogenated sodium carbonate [pH 9.6]) per well and were subsequently incubated 
overnight at 4°C. The plates were washed twice with 200 fll of TBS·block (0.01 M Tris, 0.15 M 
NaCI [pH 7.6), 0.1% gelatine) per well and were then incubated with 200 fll of TBS·block per 
well at 37°C for 2 h. The plates were then drained. Sera were diluted twofold in TBS (0.01 M 
Tris, 0.15 M NaCI [pH 7.6) starting at a dilution of 1 :200. A total of 50 fll of each serum was 
added to each well, and the plates were subsequently incubated at 3rc for 60 min. After three 
cycles of washing with TBSt (TBS with 0.04% [wtlvol] gelatin and 0.05% [vol/vol] Tween 20), 50 
fll of an alkaline phosphatase·labelled goat anti·human IgG conjugate (diluted 1:1,000 in TBSt 
[Sigma]) was added to each well; this was followed by incubation for 1 h at 37°C. A 100 fll· 
volume of acid enzyme substrate solution (9.7% diethanolamine, 3mM NaN31 5 mM 
MgCI,.6H,o, 1 mgfml p·nitrophenylphosphate [Sigma]) was added after three cycles of washing 
with TBSt and the plates were incubated at 37°C in the dark. Color development was stopped 
after 30 min of incubation by adding 100 fll of 3 M NaOH to each well. The optical densities 
at 405 nm were determined by using an automated plate reader (Bio-Tek Instruments, Inc., 
Winooski, Vt.L and it was assumed that the results of the ELISA, expressed as optical densities 
at 405 nm of the reference sera, might fluctuate at the maximum of 10%. A cutoff point was 
determined by analysis of 60 serum samples from healthy individuals of different age groups. The 
cutoff point defined the upper 5% of this population as positive by the test. Patient sera were 
regarded as positive when the results obtained by the Candida enolase ELISA were above this 
cutoff point at a serum dilution of 1 :200. Sera with positive test results were twofold diluted until 
the test results became negative, a dilution of 1 :200 was regarded as undiluted. Titers were 
defined as the highest serum dilution with a positive test result. 
Tandem XIE. Tandem XIE was performed as described by Axelsen et al. (1). Briefly, 
glassplates (5 by 5 em) coated with 1 % agarose (Sigma) in barbital buffer (pH 8.6;fl ~ 0.02) were 
used. The Candida enolase antigen (0.1 mglm/) was subjected to tandem electrophoresis (10 V 
cm-') with the purified bakers' yeast enolase antigen (20 mglml; Sigma) in the first dimension. The 
run in the second dimension against a hyperimmune rabbit serum (7,5 pl/cm 2; DAKO Glostrup, 
Denmark) or patient serum (10 pl/cm2) was performed for 18 h at 2 V cm-'. After electrophoresis, 
gels were washed first in 0.9% NaCI overnight and then in distilled water for 1 h. Finally, the gels 
were bound to agarose gelbond film (Bio-Rad laboratories, Richmond, Calif.) and stained with 
Coomassie Brilliant Blue R·250 (Sigma). 
Standard serological tests. Antibody responses against cytoplasmic antigens in the 
presence or absence of mannan, were performed as previously described (21). Briefly, titers of 
antibodies against M( +) antigen and MH antigen were measured by CIE and referred to as 
M( + )CIE and M(-)CIE respectively. Titers of circulating antigens were determined by the Cand-Tec 
assay (Ramco laboratories Inc., Houston, Tex) (2, 4) according to the directions of the 
manufacturer. A serum dilution of 1:4 or higher was regarded as a positive titer. 
Patient sera. The patient sera included in the present study were collected between 
October 1982 and January 1991. Patients were divided into two groups on the basis of clinical 
findings and culture results. Group I consisted of 76 patients with confirmed invasive candidiasis. 
The criteria for this diagnosis were based on obtaining positive Candida albicans cultures from 
tissue biopsy specimens or needle aspirates of normally sterile body cavities or at autopsy. One 
or more positive blood cultures were not adequate to classify a patient as having invasive 
candidiasis. Group II consisted of 32 C. albicans-colonized patients. Colonization was established 
by the presence of several positive C. albicans cultures of samples from different parts of the 
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gastrointestinal tract in the absence of visible lesions. 
On the basis of the immune status of the patients, both groups were subdivided into 
patients with immunodeficiencies caused by therapy or underlying diseases and patients without 
immunodeficiencies caused by therapy or underlying diseases. The criteria for immunodeficiency 
were histologically confirmed neoplasms, kidney function disorders requiring dialysis, treatment 
with corticosteroids} total-body irradiation, or the use of immunosuppressive or cytotoxic drugs. 
The majority of the patients without signs of immunodeficiencies underwent major abdominal 
surgery. None of these patients had haematological malignancies or had received treatment with 
corticosteroids, immunosuppressive or cytostatic drugs or total-body irradiation. On the basis of 
these criteria, group I patients were divided into 46 patients with signs of immunodeficiency 
(group IA) and 30 immunocompetent patients (group IB); the 32 colonized patients were divided 
into those with signs of immunodeficiency (group IIA; n= 18) and those who were 
immunocompetent (group liB; n= 14). 
Not enough serum was available from some patients to be analyzed by all serologic 
assays. Therefore, sera from only 41 patients with invasive and 18 colonized patients could be 
evaluated by the M( + )eIE and the M(-)CIE, and sera from 44 patients with invasive candidiasis 
and 18 colonized patients could be evaluated by the ELISA. Three serum samples per patient, 
when available, were included for serological evaluation. The sera were obtained, at weekly 
intervals. The first serum sample was defined as that obtained at the time of the first 
microbiological evidence of invasive candidiasis. 
Statistical analysis. Correlations between the three serum samples obtained from each 
patient were assessed using intradass correlation coefficients (rj). The capacity to discriminate 
between invasive candidiasis and colonization was evaluated by the Mann-Whitney test. 
Percentages of patients in groups I and II with a titer above cutoff levels were compared by 
Fisher's exact test. The significance level used was P=0.05 (tw(}-sided) was used. logistic 
regression was used as multivariable analysis, to evaluate simultaneously, the discriminating 
capacities of the various serological assays. 
RESULTS 
Isolation and characterization of the immunodominant antigen. Samples obtained 
from different stages of the purification procedure were examined by SDS-PAGE and 
western blotting (Fig. 1). The enzyme activities in the pooled fractions obtained during 
the different purification steps were determined in an enolase assay. After each purifi-
cation step, the specific activity of the immunodominant protein increased (Table 1). Five 
milligrams of pure C albicans enolase could be recovered from a 2-liter culture. 
Immunologic characterization of the C. albicans enolase antigen. By using the 
techniques SDS-PAGE, Western blotting and tandem XIE, Ihe C albicans enolase was 
compared with the baker's yeast enolase. The baker's yeast enolase had a molecular mass 
of approximately 49 kDa, and the Candida enolase is about 45 kDa (Fig. 2). These 
findings were confirmed by the Western blotting, in which the applied polyclonal rabbit 
anti-C albicans antiserum cross-reacted with the baker's yeast enolase. 
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Figure 1. 50S-PAGE of pooled fractions obtained during the antigen puriFication procedure. 
Lanes: 1, supernatant after shaking on a Braun shaker; 2, supernatant after 67% (NH.J2S04 
saturation; 3, dissolved pellet after 100% (NH.J2S0., saturation; 4, Candida enolase fraction after 
FPLC HLQSHP; 5, Candida enolase fraction after FPLC Mono P; 6, pooled fraction after 
concanavalin A-Sepharose chromatography; and 7, pooled Candida enolase fraction used ;n the 
ELISA. M, molecular mass markers are indicated on the right (in kilodaltons), 
Table 1. Enolase activities of different fractions during the Candida enolase antigen purification 
procedure. 
Sample Total amt. Total acitivity Sp. act. Relative Yield 
nO,a of protein (units) (unitsimg) purification ('!o) 
(mg) 
900 1,050 1. 17 100 
2 210 347 1.65 1.4 33 
3 50 149 2.98 2.6 14.2 
4 17 96 5.65 4.8 9.1 
5 14 93 6.64 5.7 8.9 
6 5 61 12.2 10.4 5.8 
.! Sample numbers: 1, supernatant after shaking on a Braun shaker; 2, dissolved pellet after 100 
% (NH4)2S0" saturation; 3, Candida enolase fraction after FPlC HLQSHPj 4, Candida enolase 
fraction after FPLC Mono Pi 5, pooled fraction after concanavalin A-Sepharose chromatography; 
and 6, pooled Candida enolase fraction used in the ELISA. 
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The antibodies of some of the patients with deep-seated candidiasis also cross-reacted 
with the baker's yeast enolase, as determined by Western blotting (Fig. 3). This cross-reac-
tivity was further analyzed by performing tandem XIE with patient sera as well as rabbit 
serum. The observed cross-reactivities on Western blots must be due to antibodies 
directed toward different epitopes, because the precipitated line formed by the Candida 
enolase antigen crosses the precipitated line formed by the baker's yeast enolase (Fig. 4). 
Immunocompetent patient group. In an earlier study, we scored by Western 
blotting the quantitative and qualitative aspects of patient sera against the 
immunodominant antigen (19). To study the diagnostic accuracy of specific antibodies 
directed towards the immunodominant Candida enolase antigen, sera of different patient 
groups were examined in an ELISA. Only IgG antibody titers were determined. 
Antibodies directed towards the Candida enolase antigen studied in the 
immunocompetent patient group showed increased antibody titers over time. However, 
the increase in antibody titers with time was not significant. Since these titers were 
strongly correlated (r;~O.72), the mean titers of serum samples 1, 2, and 3 from each 
patient was calculated, after logarithmic transformation, and were used to discriminate 
between invasive candidiasis (group 18) and colonization (group liB). 
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Figure 2. Comparison of molecular masses obtained by 50S-PAGE and antigenicity by Western 
blotting of 1 and 5, baker's yeast enolase; 2 and 6, baker's yeast enolase after Mono Q 
Sepharose column chromatography; 3 and 7, Candida enolase antigen; 4 and 8, partially purified 
Candida extract. Lanes 1 to 4 were stained with Coomassie brilliant blue, and lanes 5 to 8 were 
incubated with hyperimmune rabbit serum. M, molecular mass markers are indicated on the left 
(in kilodaltons) 
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Figure 3. Western blots of baker's yeast enolase and C. albicans enolase obtained by exposure 
to sera from two patients with invasive candidiasis. Lanes: 1 and Sf baker's yeast enolase; 2 and 
6, baker's yeast enolase after Mono Q Sepharose column chromatography; 3 and 7, Candida 
enolase antigen; 4 and 8, partially purified Candida extract. Lanes 1 to 4 and 5 to 8 were 
incubated with sera obtained from two patients with invasive candidiasis, respectively. Numbers 
on the left are molecular masses (in kilodaftons). 
Figure 4. Tandem XIE demonstrating rabbit antibodies directed toward the Candida enolase 
(arrow A) and the baker's yeast enolase (arrow 8), 
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Figure 5 shows the mean logarithm(titer + 1) for each individual patient in groups 
IB and liB. A cutoff value of ;" 2 for anti-Candida enolase antibody levels gave the best 
sensitivity and specificity, i.e., 50 and 86%, respectively (Table 2). When sera from 
healthy individuals were used as negative control group, the specificity increased to 
100%. 
Antibody titers determined with the M( + )CIE, which were conducted on the same 
sera from each patient from groups IB and liB, gave a better sensitivity but a lower 
specificity, while the M(-)CIE also had a better sensitivity but a specificity comparable to 
that of the enolase ELISA at the indicated cutoff values (Table 2). When the mean 
log(titer+ 1) of antigen of the serum samples per patient was calculated, a sensitivity of 
27% and a specificity of 86% were established. 
Table 2. Sensitivities and specificities of the different tests determined at a chosen cutoff value 
by using the mean !ogarithm(titer+ 1) values obtained for groups I and II of the 
immunocompetent patient group. 
Serological assay Cutoff Sensitivity Specificity P valuea 
value (%) (%) 
M(+)CIE ;,,2 80 29 0.4 
M(-)CIE ;,1 70 79 0.004 
Enolase ELISA ;,,2 50 86 0.02 
Enolase ELISA ;,,2 SOb 100b 3.3xl0·9 
Cand-Tec ;,4 27 86 0.46 
a P values were determined by the Fisher exact test by comparing percentages of patients in 
groups IB and liB whose sera had titers above the cutoff levels. 
b Sera from healthy individuals were used to calculate the sensitivity, the specificity, and the P 
value. 
When calculating the sensitivity and specificity for the first serum sample obtained 
from each patient group from which three serum samples were available, a sensitivity of 
47% and a specificity of 71 % were established. However, if the mean value for three 
serum samples for the same selected group of patients was calculated, the sensitivity 
decreased to 21 % and the specificity was 100%. In both situations, the Cand-Tec did not 
discriminate between invasive candidiasis and colonization (p~0.33 and P~0.53, 
respectively). Three serum samples were available from 13 immunocompetent patients 
with invasive candidiasis and 6 immunocompetent colonized patients. 
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Multivariable analysis showed that the antibody assays, i.e. Candida enolase ELISA, 
or the M(+)CIE and the antigen detection assay Cand-Tec did not improve the 
discriminative capacity relative to that of the M(-)CIE. 
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Figure 5. Distribution of the mean !ogarithm(titer + 1) of anti-Candida enolase antibodies in the 
sera of each immunocompetent patient with invasive candidiasis (I) or Candida colonization (II), 
Immunodeficient patient group. In comparison with the titers in the sera from the 
immunocompetent patient group, anti-Candida enolase antibody titers in sera of the 
immunodeficient patients did not increase significantly over the 2-week interval of 
observation. Again, the titers in serum were transformed as mentioned above, and the 
mean logarithm(titer + 1) values are depicted in Fig. 6. Statistical analysis of these data 
showed that the mean logarithm(titer + 1) levels, obtained by the Candida enolase ELISA 
were significantly higher for patients with invasive candidiasis than patients colonized 
with C. albicans (P ~0.03; Mann-Whitney test) without a chosen cutoff value. At a cutoff 
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value of ;0, 1, the test had a sensitivity of 53% and a specificity of 78% (Table 3). Again 
the specificity of the assay increased when sera from healthy individuals were used as a 
negative control group (Table 3). Although, the increase in antibody titers with time was 
not significant, the sensitivity of the test increased from 42 to 54% for the first serum 
sample obtained from each patient, while the specificity remained constant (78%). 
The results obtained by the M( + )CIE, M(-)CIE, and Cand-Tec antigen detection 
assays in the immunodeficient patient group are depicted in Table 3. The Candida 
enolase ELISA was the only antibody detection assay that was able to discriminate 
between invasive candidiasis and colonization. By multivariable analysis, it was found 
that the antigen detection assay Cand-Tec was somewhat better at discriminating invasive 
candidiasis and colonization. Combining the results of Cand-Tec with those of Candida 
enolase ELISA did not improve the discriminative capacity relative to that of the Cand-Tec 
alone. 
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figure 6. Distribution of the mean (ogarithm(titer + 1) of antibody directed toward the Candida 
enolase in the sera of immunodeficient patients with invasive candidiasis (I) or colonization (II). 
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Table 3. Sensitivities and specificities of the different tests determined at a chosen cutoff value 
by using the mean /ogarithm(titer+ 1) values obtained for groups I and /I of the immunodeficient 
patient group. 
Serological assay Cutoff Sensitivity Specificity P valuea 
value ('!o) ('!o) 
M(+)CIE ;,2 69 39 0.79 
M(-)CIE ;,1 31 83 0.35 
Enolase ELISA ;,1 53 78 0.046 
Enolase ELISA ;,1 53b 95b 2.0 x 10 • 
Cand-Tec ;,4 54 78 0.026 
a P values were determined by the Fisher exact test by comparing percentages of patients in 
groups 18 and liB whose sera had titers above the cutoff levels. 
b Sera from healthy individuals were used to calculate the sensitivity, the specificity, and the P 
value. 
DISCUSSION 
It is known, from the literature and from our own investigations that antibody 
responses against the 47 kDa antigen are frequently found in sera of patients with 
invasive candidiasis (17, 19). In order to develop a quantitative assay, we purified the 
immunodominant antigen and coated it onto ELISA plates in an attempt to try and detect 
specific antibodies directed against this antigen. Furthermore, the purified antigen was 
characterized by different techniques to solve the enigma as to whether we were dealing 
with the 47 kDa immunodominant antigen or an enolase antigen or whether both 
characteristics were gathered into one and the same antigen. 
From the results that we observed, we must conclude that the molecular mass of 
the immunodominant antigen is 45 kDa and that our purified immunodominant antigen 
also has enolase activity. These findings have also been reported by others (7, 12, 16, 
22). In accordance with the results found by Mason et al. (16), we also conclude from 
the results of the immunoblot analysis that antigenic cross-reactivity exists between our 
45 kDa antigen and a commercial baker's yeast enolase. Recently, Kortekangas-Solvainen 
et al. (14) also demonstrated by Western blotting the cross-reactivity of IgE antibodies 
directed toward a 48 kDa band of Saccharomyces cerevisiae, a 46 kDa band of C. 
albicans, and the purified baker's yeast enolase. However, from our tandem XIE results 
we concluded that these cross-reacting antibodies are directed against different epitopes, 
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which was also reported by Franklyn et al. (7). 
The Candida enolase antibody ELISA was reproducible, as measured by day to day 
variation tests, and was specific for antibodies directed against Candida enolase antigen, 
as determined by inhibition experiments (data not shown). The Candida enolase antibody 
ELISA had a diagnostic value at a cutoff point of ;"2 in the immunocompetent patient 
group with an acceptable specificity (86%) but a low sensitivity (50%). Multiple serum 
samples were necessary to maximize detection, as observed by the fact that sensitivity 
increased slightly, from 47 to 50%, when more than one serum sample was used to 
determine diagnostic accuracy of the test, whereas the specificity was maintained (86%). 
In this immunocompetent patient group, an increase in specificity was observed when 
compared with the data obtained by the M(+)CIE and, to a lesser extent, the M(-)CIE. 
Despite the use of a more sensitive detection assay, i.e., ELISA as opposed to the CIE, the 
increase in specificity of the enolase test was counteracted by a loss in sensitivity, i.e., 
a decrease from 80 to 50%, compared to the M( + )CIE. 
For the immunodeficient group, the Candida enolase ELISA showed significantly 
higher titers in the sera of patients with invasive candidiasis than in the sera of patients 
colonized by C. albicans. However, the sensitivity of the assay for sera from the 
immunodeficient patient group was also low (53%), with a specificity of 78%. In the 
immunodeficient patient group, patients with leukemia did not respond at all with 
antibodies directed toward the Candida enolase antigen. Consequently, when all 
leukemic patients in both subgroups IA and IIA were excluded from the immunodeficient 
patient group for analysis, the assay's sensitivity (64%) as well as specificity (90%) 
increased (p~0.0036; Fisher exact test). 
Greenfield et al. (9) also reported a low sensitivity (25%) and a high specificity of 
(97.8%) for their assay, which was based on a purified 54 kDa major cytoplasmic 
antigen. On the other hand, Zoller et al. (23) reported a sensitivity of 81.5% and a 
specificity of 96.4% for their ELISA with 47-29 kDa antigens of C. albicans. The 
difference between their data and our own is probably due to different criteria used for 
patients with invasive candidiasis as well as the fact that patients with 
immunodeficiencies and immunocompetent patients were regarded as a homogeneous 
group. The use of different cutoff values, which is necessary for the correct evaluation of 
the titers obtained for immunocompetent patients and immunodeficient patients, also 
explains the different interpretation of the results obtained for these groups. 
The Cand-Tec assay had a good discriminating capacity for sera from the 
immunodeficient patient group. However, the sensitivity and specificity of the Cand-Tec 
assay were not as favourable as those determined by other investigators (4, 8); the 
sensitivity of the test for sera from both patient groups (IA and 18) was low, while the 
specificity was acceptable. Discrepancies may be due to different selection criteria used 
for determining invasive candidiasis. The test is probably more useful during the early 
stage of disease, since additional sera from each patient, which were obtained later in the 
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course of invasive Candida infection, did not improve diagnostic sensitivity of the test. 
This was also found by Herent et al. (10). 
Previously reports of antibody detection assays with crude antigens for the 
detection of deep-seated candidiasis always showed that the tests suffered from 
suboptimal sensitivities or specificities (11). The lack of specificity is due to the fact that 
most healthy individuals already have antibodies directed against cell wall components 
of C. albicans (6). Therefore, it is conceivable that the use of a purified, well-defined 
antigen rather than a crude extract containing cell wall polysaccharide provides a more 
specific test for systemic candidiasis. Since it has already been demonstrated that the 
enolase antigen is released during the progression of infection and that it elicits a specific 
antibody response (17), it would be conceivable that this particular antigen could be 
applied in an antibody detection assay. In the present study, we have demonstrated that 
the detection of anti-enolase antibodies results in a discriminative test with a low 
sensitivity but an acceptable specificity. Because of its good specificity, results of this 
particular test, in contrast to previously described assays, supports the clinician in making 
the decision whether to start with toxic antifungal agents. Whether anti-enolase antibodies 
can be used in monitoring the response to treatment and in determining the duration of 
therapy must be investigated. 
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ABSTRACT 
In studying the anti-mann an antibodies longitudinally in serial serum samples of 
three immunocompromised patients, it was observed that anti-mann an antibodies started 
to increase shortly after the moment that cultures of deep-tissue sites became positive 
with C. albicans. 
The mean anti-mann an antibody titers determined in a group of 36 
immunocompromised patients with invasive candidiasis increased within two weeks after 
the probable onset of invasive candidiasis. In contrast, anti-mannan antibody levels in 
serial serum samples of 14 immunocompromised patients who were only colonized with 
C. albicans remained stable or decreased in time. The HA test measuring the anti-mannan 
antibodies was 64% sensitive and 89% specific in determining invasive candidiasis. In 
contrast, antibodies specific for candidal cytoplasmic antigens or enolase alone were of 
little value in confirming invasive candidiasis in these immunocompromised patients. 
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INTRODUCTION 
The yeast C. albicans is a commensal in the human digestive tract and rarely 
causes invasive disease in the normal individual. However, when the bacterial flora is 
changed or the host immune system weakened, C. albicans can overgrow and cause 
infection (11). It is currently difficult, if not impossible, to define a point in time at which 
a mass of yeasts makes the transition from commensalism to a pathogenic state (1). Since 
biopsies cannot be performed routinely, and the sensitivity of blood cultures is limited 
(2), it would be helpful to have reliable serological assays that support or refute the 
clinical diagnosis of invasive candidiasis. 
Unfortunately, in immunocompromised patients results of serological tests, 
especially antibody detection tests, are often difficult to interpret due to the suppression 
or even complete absence of an immune response (19, 20). Furthermore, serology based 
on a single serum sample is biased by the time of sampling during a given stage of the 
Candida infection, thus giving rise to false-negative results. This particular shortcoming 
of serology can be overcome by serial sampling, in which the increase or fall of an 
antibody titer is a more reliable reflection of the correct diagnosis (8, 10, 13). In this 
manner we evaluated the levels of several antibodies and antigens in relation to the 
pathogenesis of candidiasis in immunocompromised patients. 
MATERIALS AND METHODS. 
Haemagglutination assay. Antibodies directed against cell wall mannan were determined 
by haemagglutination (HA) (15). The mannan containing antigen was prepared from C. albicans 
CBS 5982 by means of natamycin degradation as described earlier (7), and coupled to sheep 
erythrocytes with concanavalin A. 
Counterimmunoelectrophoresis. Antibodies directed against a mixture of cytoplasmic 
antigens with and without mannan were measured by counterimmunoelectrophoresis (CIE) as 
described previously (22). These assays will be referred to as M( + )ClE and M(-)CIE, respectively. 
Depletion of the cytoplasmic antigens from mannan and glycoproteins was accomplished by use 
of a concanavalin A-Sepharose column as described by Ellsworth et al. (4). 
Antigen detection by Cand·Tec. For antigen detection the Cand-Tec test (Ramco 
Laboratories Inc., Houston, Tex.) was used as described by the manufacturer. 
Patient sera. Patient sera were collected between October 1982 and January 1992. All 
results, including underlying diseases, therapy as well as of serological data were collected 
retrospectively. Only patients infected by the species Candida albicans were included in the 
present study. All patients included in this study had evidence of immunodeficiencies caused by 
therapy or underlying diseases. The criteria for immunodeficiency were histologically confirmed 
neoplasms, kidney function disorders requiring chronic dialysis, treatment with corticosteroids, 
total-body irradiation, or the use of immunosuppressive or cytotoxic drugs. Patients were divided 
into two groups on the basis of clinical findings and culture results. Group I consisted of 36 
patients with clinically confirmed invasive candidiasis. The criteria for this diagnosis were based 
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on obtaining positive C. albicans cultures from tissue biopsy specimens or needle aspirates of 
normally sterile body cavities. Biopsies from such sites taken at autopsy which grew C albicans 
were likewise taken as evidence for invasive candidiasis. If only one or more positive blood 
cultures were obtained these were not regarded sufficient to classify a patient as having invasive 
candidiasis and these patients were not included in this study. Group I included 9 leucopenic 
patients receiving either chemotherapy, corticosteroids, immunosuppressive drugs or a 
combination therapYi 4 patients with kidney function disorders requiring dialysis combined with 
therapy with corticosteroids; 8 patients with histologically confirmed neoplasms; 2 patients with 
HIV; 2 patients with cancer receiving corticosteroids; 4 patients after organtransplants receiving 
corticosteroids and immunosuppressive drugs, and 7 patients on corticosteroids or receiving 
immunosuppressive drugs after surgical interventions. 
Group II consisted of 14 patients colonized by C. albicans. Colonization was deemed to 
exist if more than 2 cultures of samples from different parts of the gastrointestinal tract were 
positive for C. albicans in the absence of visible lesions. As invasive candidiasis might have been 
present subclinically in the group of colonized patients, patients were excluded from this study 
if they were treated with antifungal agents or if their fever did not react to antibacterial agents 
within three days. This group included 8 leucopenic patients receiving either chemotherapy, 
corticosteroids, immunosuppressive drugs or a combination therapy, one patient with kidney 
function disorders requiring dialYSis combined with corticosteroids, two patients with cancer 
receiving corticosteroids, two patients with histologically confirmed neoplasms, and one patient 
underwent livertransplantation receiving immunosuppressive agents and corticosteroids. 
Serial serum samples taken at weekly intervals from each patient, were included for 
serological evaluation. The first serum sample was defined as the sample obtained at the time of 
the first microbiological evidence of invasive candidiasis or Candida albicans colonization. The 
HA, M(+)CIE, and the Cand-Tec assay were performed on freshly obtained serum samples, and 
serum samples were kept frozen at -70°C thereafter. Since it was not always possible to collect 
three multiple. serial sera from each patient, group I included 23 patients with three sera, and 13 
with two sera. Group II included six patients with three sera, and eight with two sera. 
To determine sensitivity and specificity of the serological assays the mean of the 
logarithmically transformed titer values of the sera of each patient were used. Titer values from 
the sera of each patient were first logarithmically transformed, logarithm(titer + 1), before the 
mean logarithm titers of the sera was calculated for each patient. 
Statistical analysis. Correlation between the three or two serum samples obtained from 
each patient were assessed by using intraclass correlation coeffients (r j). The capacity to 
discriminate between invasive candidiasis and C. albicans colonization was evaluated by the 
Mann-Whitney test. The percentage of patients in groups I and II with titers above the cutoff levels 
were compared by Fisher's exact test. A significance level of p=o.OS (two-sided) was used. 
RESULTS 
Antibody response and antigen titers in three immunocompromised patients. To 
study titer kinetics of anti-mannan and anti-cytoplasmic C. albkans antibodies and 
antigen levels three immunocompromised patients with invasive candidiasis were 
monitored over a period of 11 weeks. 
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Patient 1. An l8-year-old man was readmitted to the hospital for residual myeloid 
leukemia. On hospital day two, serology revealed an antibody titer of 1:2 in the M( + )CIE 
and an anti-mann an antibody titer of 1 :64 as determined by HA (Fig. 1). The antigen 
assay initially gave a titer of 1:8 and a negative result was obtained in the M(-)CIE (data 
not shown). The patient developed fever on hospital day 33 and blood cultures were 
taken that grew C. albicans. Treatment with amphotericin Band flucytosine was started. 
Flucytosine treatment was stopped after 10 days because of hepatotoxicity. An X-ray of 
the thorax taken on day 39 showed infiltrations that were compatible with the diagnosis 
of pulmonary candidiasis. During the period of treatment anti-mannan antibodies further 
increased and after three weeks stabilized at a titer of 1:8 as determined by M( + )CIE. 
Anti-mannan antibody titers detected by HA had increased to 1 :4096. However, anti-
cytoplasmic antibody, [M(-)CIE], titers remained undetectable, and Cand-Tec antigen titers 
were low. After a total accumulated dose of 1 gram of amphotericin B the treatment was 
stopped. On hospital day 70 C. albicans was cultured from a broncho alveolar lavage 
specimen and treatment with itraconazole was started. At day 73 blood cultures again 
grew C. albicans and itraconazole was switched to amphotericin B. On day 78 the 
patient died but no autopsy was performed. 
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Figure 1. C. albicans antibody and antigen titers determined by HA, M(+)ClE, and Cand-Tee in 
sera of immunocompromised patient 1 during his hospital stay, are transformed to !ogaritIJln(titer 
+ 1) values. Boxes indicate the time the patient received f1ucytosine (f/ucyt.), amphotericin B 
(ampho B), and irraconazole (irrac.). C. albicans was cultured twice from blood (days 33 and 73) 
and once from broncho-alveolar lavage (lung) (day 70) as indicated by arrows. (HA = -0-, 
M( + )C/f ~ _B_, Cand-Tec ~ _e_). 
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Patient 2. A 36-year-old woman with acute myeloid leukemia was hospitalized 
for chemotherapy. During chemotherapy she received oral amphotericin B prophylaxis. 
Despite the prophylaxis cultures from throat, feces, urine, and vagina were positive for 
C. albicans. Antibodies as determined by M(+)CIE, were 1:1 (fig. 2). On day 72, 
antibodies directed towards mannan increased to 1:2 which was accompanied by an 
increase in antigen titers. The mannan-antibody titers as determined by HA were low 
(1 :2) or could not be detected during the rest of the hospitalization period. On day 70 
blood cultures became positive with C. albicans as well as cultures from feces and urine. 
Treatment with amphotericin B was started but nine days later patient died. Cultures 
taken at autopsy revealed C. albicans in spleen, liver, and gastrointestinal tissue. 
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Figure 2. C. a/bicam antibody and antigen Uters determined by HA, M(+)C1E, and Cand-Tec in 
sera of immunocompromised patient 2 during her hospital stay, are transformed to /ogarithm(titer 
+ 1) values. Boxes indicate the time the patient received amphotericin B profylaxis and 
amphotericin B i. v. treatment. C. albicans was cultured several times from blood (day 70) as 
indicated by arrows, and from throat, feces, urine, and vagina during the whole hospital stay. 
(HA ~ -0-, M(+)CfE ~ -B., Cand-Tec ~ _O_) 
Patient 3. A 24-year-old woman with systemic lupus erythematosus was 
hospitalized because of fever, nephrotic syndrome and anemia. She did not respond to 
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the antimicrobial agents administered emperically, and on day four she developed 
respiratory insufficiency which was due to infection with Legionella pneumophila. 
Erythromycin treatment was started. Initially, the patient seems to improve after 
erythromycin therapy. However, on day 8 Candida oesophagi tis was visualized by 
gastroscopy and treatment with ketoconazole was started. Anti-mannan-antibodies, 
detected by HA, increased from 1:4 at day 0 to 1 :512 at day 11 (Fig. 3). Antibody titers 
in the M( + )CIE also increased from undetectable to 1:4 in the same period and fluctuated 
thereafter. The Cand-Tec antigen titers were low, but fluctuated apparently contrary to the 
M( + )CIE antibody titers. Candida was still present in the throat, feces, and vagina on day 
70. Eventually, she died on hospital day 77. At autopsy C. albicans was cultured from 
the lungs and the duodenum. 
Thus, the kinetics of anti-mannan antibody response as determined by HA and 
M( +) CIE seemed to be associated with the onset of invasive candidiasis. Therefore we 
decided to study these responses in a larger population of immunocompromised patients. 
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Figure 3. C. albicans antibody and antigen titers determined by HA, M( + )CIE, and Cand-Tec in 
sera of immunocompromised patient 3 during her hospital stay, are transformed to /ogarithm(titer 
+ 1) values. Boxes indicate the time the patient received ketoconazole. C. albicans oesophagitis 
was established at day 8 indicated by the arrow and high numbers of C. albicans from throat, 
feces and vagina at day 70. (HA ~ -0-, M(+)CIE ~ -.-, Cand·Tec ~ -.-). 
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Kinetics of mannan-antibody response in immunocompromised patients. In the 
group of patients with invasive candidiasis (I) the mean titer of anti-mannan antibodies, 
as determined by HA, increased from the moment that cultures became positive (serum 
1, mean of 1.04) up to 14 days thereafter (serum 3, mean of 1.48) (Fig. 4). Kinetics of the 
anti-mannan antibody response expressed as a change from a negative titer to a positive 
titer or a doubling of a positive titer result, occurred in 14/36 (38.9%) of the paired sera. 
However, this increase in titers determined by HA was less than twofold and did not 
reach statistical significance (ri~0.73). In contrast, the level of mannan-antibody in the 
sera of colonized patients (group II) was lower and did decrease rather than increase over 
time (Fig. 4). 
The anti-mannan antibody titers of the first serum samples, were already 
significantly higher from patients with invasive candidiasis than those colonized with C. 
albicans (P < 0.01; Mann-Whitney test). The anti-mannan antibody titers of the sera one 
and two weeks after the probable onset of the invasive infection were also significantly 
higher in patients with invasive candidiasis (P < 0.01; Mann-Whitney test). 
Statistical analysis of all patients showed that the mean logarithm(titer + 1) of HA 
antibody levels are significantly higher in patients with invasive candidiasis than in those 
colonized with C. albicans irrespective of a cutoff value (p~0.01; Mann-Withney test). 
Using a cutoff value of 2:8 the HA test had a sensitivity of 64% and a specificity of 89% 
(p~0.004; Fisher exact test). 
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Figure 4. Box plots of anti~mannan antibody titers in immunocompromised patients with invasive 
candidiasis (group I, n = 64) and in immunocompromised patients only colonized with C. albicans 
(group n n = 18). The boxes represent the 25111 percentile to the 7Slh percentile of anti-mannan 
antibody titers as determined by HA in serial sera (1, 2, and 3) taken at weekly intervals with a 
horizontal line at the median (srf' percentile). Whiskers indicate the total range of the titer values 
observed. 
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Kinetics of antibody response in immunocompromised patients determined by 
elE. The M( + )CIE detects precipitating antibodies directed against a crude mixture of C. 
albicans antigens including mannan. The mean M( + )elE antibody titer in group I patients 
tended to increase but this increase was not statistically significant (rl~0.76) (Fig. 5). 
Again, in 14 of the 36 paired sera (38.9%), a change from a negative titer to a positive 
titer or a doubling of a positive titer in the M( + )elE occurred. Only a few patients in the 
colonized patient group" had precipitating antibodies and they did not increase in titer 
over a period of two weeks (Fig. S).The M( + )elE antibody levels were significantly higher 
in the first serum samples from patients with invasive candidiasis than in those colonized 
with C. albicans (P < 0.01; Mann-Whitney test). The M( + )elE antibody titers in serum 
samples 2 and 3 are significantly higher in patients with invasive candidiasis. Taken the 
mean logarithm(titer + 1) of the two or three sera per patient and using a cutoff value 
of ;"2 a sensitivity and specificity of 58 and 79% was obtained (P~0.03; Fisher exact 
test). 
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Figure 5. Box plots of anti~mannan antibody titers in immunocompromised patients with invasive 
candidiasis (group I, n = 64) and in immunocompromised patients only colonized with C. albicans 
(group'" n= 18). The boxes represent the 25th percentile to the 75th percentile of anti~mannan 
antibody titers as determined by M( +)CIE in serial sera (I, 2, and 3) taken at weekly intervals 
witll a horizontal line at the median (5(jh percentile). Whiskers indicate the total range of the titer 
values observed. 
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To evaluate the contribution of antibodies directed against cytoplasmic antigens 
as opposed to cell wall mann an the crude C. albicans extract was depleted of mannan 
and glycoproteins. Since antibody detection by M(-)CIE was performed on serum samples 
that had been kept frozen at -lO°C, we also repeated the M( + )CIE on the frozen samples 
to rule out discrepant results due to degradation of antibodies or antibody-antigen 
complexes during storage. In general the titers obtained in the M( + )CIE performed on 
frozen serum samples were somewhat higher than those in the M( + )CIE performed prior 
to freezing (data not shown). Removal of the mann an moiety from the crude C. albicans 
antigen mixture resulted in low anti-cytoplasmic antibody titers (mean of 1 :1) for the 
patients with invasive candidiasis and less than 1:1 for the colonized patient group (data 
not shown). 
Kinetics of antigen titers in immunocompromised patients determined by Cand-
Tee. Our results with the Cand-Tec antigen test showed that antigen titers remained 
constant during the two week observation period in sera of patients with invasive 
candidiasis (data not shown). Only in 6 of the 36 paired sera (16.6%), a change from a 
negative titer to a positive titer or a doubling of a positive titer occurred. For colonized 
patients the antigen titers were significantly lower and in general decreased with time. 
The mean (logarithm(titer + 1» of antigen levels, were significantly higher in patients 
with invasive candidiasis than in patients colonized with C. albicans (P<O.01; Mann-
Whitney test), and resulted at a cutoff value of ;, 2 in an assay sensitivity and specificity 
of 69 and 64%, respectively (P~O.05; Fisher exact test). 
DISCUSSION 
In the present study we gained insight into which assay is most valuable in the 
confirmation of invasive candidiasis by monitoring the kinetics of the antibody response 
and of antigen titers. 
It is remarkable that in two of the three immunocompromised patients studied 
longitudinally over 11 weeks, antigen titers were low despite the fact that all three were 
clearly suffering from invasive candidiasis. These findings indicate that the antigen is not 
sufficiently detected by the Cand-Tec assay, possibly because free antigen is not released 
into the circulation; this may be due to insufficient processing of Candida cells due to the 
impaired cellular response of these patients, as suggested by Mohart et al. (16). Therefore, 
antigen detection systems may not automatically be the serological test of choice in 
immunocompromised patients as suggested by others (12, 21). In contrast, anti-mannan 
antibody was detected by M(+)CIE and HA, and started to increase shortly after the 
moment that cultures of deep-tissue sites became positive with C. albicans. Although 
antibodies directed against mannan are known to be universally present in normal human 
sera, most likely as a consequence of mucocutaneous colonization (3, 5, 14)1 changes in 
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the titers of anti-mannan antibody were positively correlated with the occurrence of 
invasive candidiasis in immunocompromised patients. Greenfield et al. (6), also 
demonstrated the utility of mannan-serology for candidiasis in patients treated for acute 
leukemia. The diagnostic use, however, of anti-Candida antibodies in 
immunocompromised patients remains a controversial issue (9, 18, 19, 24). Immunoblot 
analysis has been extensively used to identify specific immunogenic components of C. 
albicans that correlated well with invasive candidiasis. Despite the fact that specific 
immunogenic components provided greater specificity for invasive candidiasis than 
mann an antigens did, the sensitivity of these assays for invasive disease decreased for 
patients profoundly immunocompromised (19). On the other hand, titers for antibodies 
to C. albicans germtubes or blastospores, which are anti-mann an antibodies 
predominantly, were detectable in sera of immunocompromised patients with invasive 
candidiasis, and might be used diagnostically (18, 24). In these studies only the height 
of the titer of antibody was influenced by the patient's immunological status. In our 
immunocompromised patient group, an increase in anti-mannan antibody titers was 
observed in the first two weeks after the first clinical signs of invasive candidiasis had 
appeared. In contrast, anti-mann an antibody titers in sera of immunocompromised 
patients that were only colonized with C. albicans were significantly lower and tended 
to decrease. The fact that anti-mannan antibody levels increase so quickly in patients with 
invasive disease is compatible with a secondary immune response to an antigen against 
which antibodies are already present in normal human sera (15). The follow-up of anti-
mannan antibody titers for detection of Candida infection was recently confirmed in a 
study of children with malignant disease and invasive candidiasis (17). However, anti-
mannan antibodies in this particular study appeared slowly since the childrens antibody 
response is a primary immunoresponse and not a secondary one, as is the case with adult 
patients. 
The moderate sensitivity of the HA assay might be caused by two phenomena, in 
the first place anti-mannan antibodies might not be detected due to a decrease in titer as 
a result of anti-mannan antibodies interacting with mannan or with whole C. albicans 
cells released during invasive infection or secondly by a too early or too late blood 
sampling during the infectious process. This however can partly be overcome by serial 
sampling as shown in the present study. 
The antibody response toward cytoplasmic antigens of C. albicans in our patients 
was poor. This was not the result of the use of frozen serum samples since the anti-
mannan antibody titers as determined by M( + )CIE were about the same in frozen serum 
samples compared to titer values in the same sera prior to freezing. The immune 
response toward C. albicans cytoplasmic components is poor, probably because it 
constitutes a primary immune response (8), In immunocompetent surgical patients, 
however, we previously demonstrated that the M(-)CIE assay discriminated well between 
those with invasive candidiasis and those with colonization alone (23). Thus, different 
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serological assays may be needed for the diagnosis of invasive candidiasis in patients with 
different types of underlying diseases. 
The antigen titers determined by the Cand-Tec assay remained stable OVer time in 
immunocompromised patients with proven invasive candidiasis, while in patients that 
were only colonized antigen levels decreased in time. Although, antigen titers were 
generally low in these patients, their persistence during the course of hospitalization 
could further support the diagnosis of invasive infection. 
We conclude, that the anti-mannan antibody assays are of clinical value in 
immunocompromised patients. They may help to confirm the clinical diagnosis of an 
invasive Candida infection. Documenting increases in antibody titer during the 
progression of infection is recommended since it avoids the limitations of interpreting the 
test results on a single serum sample. Measuring changes in the level of anti-mannan 
antibodies seems to be more sensitive than the detection of cytoplasmic antigens or 
antibodies directed against cytoplasmic antigens as indicator for invasive candidiasis in 
immunocompromised patients. 
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ABSTRACT 
A PCR using primers aimed at the multicopy gene coding for the small subunit 
rRNA and resulting in the synthesis of a 180-bp fragment was evaluated for its use in 
diagnosing invasive candidiasis in comparison with blood culture. With the use of a C. 
albicans-specific probe, ± 10 to 15 C. albicans cells are detected in 100 pi of whole 
blood by Southern analysis. A DNase pretreatment was critical in the purification process 
of yeast DNA from whole blood. Omission of the DNase pretreatment decreased assay 
sensitivity la-fold. PCR analysis of blood-specimens collected from mice with invasive 
candidiasis is more sensitive than blood culture (100 versus 67 %, respectively) at 72 h 
after intravenous (Lv.) inoculation with C. albicans. Furthermore, the intensity of the 
hybridization signals increased with the progression of infection. In contrast, multiple 
blood samples from gastrointestinally colonized mice were all negative by PCR, 
indicating that the PCR assay is also specific and may, therefore, have a positive 
contribution to the detection and follow-up of invasive candidiasis. 
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INTRODUCTION 
The opportunistic pathogen Candida albicans is able to cause disseminated 
infections in immul1ocompromised patients. To reduce mortality in patients with invasive 
candidiasis, early initiation of antifungal drug therapy is critical (1). The clinical diagnosis 
is complicated because C. albicans commonly colonizes or causes mild infection of the 
mucous membranes or skin. It is, therefore, often difficult to judge the clinical 
significance of the finding of c. albicans in secretions or on the body surfaces when 
systemic infection is suspected in case of occult fever or for other reasons. 
Microbiological evidence for the diagnosis of invasive candidiasis requires the 
demonstration of C. a/bicans in sterile body fluids, biopsies or in multiple consecutive 
blood cultures (7). There are, however, many problems inherent in these tests (12). 
Berenguer et al. (2), for instance, recently demonstrated that even by application of the 
Iysis·centrifugation technique, a sensitivity of only 43% Was established in autopsy-proven 
cases of invasive candidiasis. They also demonstrated that the sensitivity of the Iysis-
centrifugation blood culture technique correlated with the number of infected tissue sites, 
and therefore, these investigators stressed the need for more sensitive methods for 
detection of invasive candidiasis. 
Since PCR has proven to be a powerful tool in the early diagnosis of several 
infectious diseases, it might also be a more sensitive alternative assay in the diagnosis of 
invasive candidiasis. Several PCR methods for the detection of Candida spp. in patient 
materials have been published (3, 6, 8, 10). However, the diagnostic usefulness of PCR 
remains to be established because of the reported limitations of the technique when 
whole blood is used (6, 8), the lack of verification with a species-specific probe for the 
amplified product (3) and the inability to detect medically important Candida spp. other 
than C. albicans (11). 
The application of PCR in the early diagnosis of systemic candidiasis has to be 
ascertained in comparison with that of the blood culture technique, and furthermore, PCR 
results must be negative in patients who are merely colonized with C. albicans. In the 
present study the diagnostic usefulness of PCR was studied by detecting C. a/bicans in 
whole blood of systemically infected mice and in gastrointestinally colonized mice in 
order to determine the sensitivity and accuracy of the PCR assay for discriminating 
between colonization and invasive candidiasis. 
MATERIALS AND METHODS 
Animals and Candida strain. Specifk-pathogen-free, 11- to 13 weeks-old female BALS/c 
mice weighing ± 22 g were used (lffa Credo, L'Arbresle, France). C. albicans (ATCC 44858) was 
used throughout all the experiments. The yeast was stored at -BO°C in Todd-Hewitt broth (Difeo 
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Laboratories, Detroit, Mich,) containing 10% (vol/vol) glycerol. Stationary-growth-phase cultures 
were obtained after incubation of the yeast in Sabouraud maltose broth (Difco laboratories) for 
24 h at 37°C. Yeasts were washed in phosphate-buffered saline (PBS), counted in a 
hemocytometer, and adjusted to 5 x 104 cells per ml in PBS. 
Systemic infection in neutropenic mice. Neutropenia was induced by intraperitoneal 
administration of cyclophosphamide (Sigma) at 100 mg/kg of body weight 4 days prior to 
inoculation with C. albicans, followed by additional doses of 75 mglkg on the day of inoculation 
and at 3-day intervals during the course of infection (14). This treatment resulted in persistent 
granulocytopenia of < 100 granulocytes per pi of blood from the time of inoculation with C. 
afbicans up to termination of the studies. In each experiment 21 neutropenic mice were infected 
by inoculation of 200 III of 5 x 10' CFU of C. albicans per 011 in the tail vein. 
At 1, 6, 24, 48, 72, 96, and 144 h after inoculation with C. afbicans, the mice were 
sacrificed, using three mice for each time point. At the above-indicated time intervals, blood was 
collected in EDTA-coated tubes by cardiac puncture. Of each blood sample, 100 /11 was directly 
cultured on Sabouraud dextrose agar (SDA) plates (Oxo'id, Basingstoke, England) and incubated 
for 5 days at 37°C Another 100 III of blood was used for DNA extraction. 
The kidneys, spleen, liver, and lungs were removed from each mouse and separately 
homogenized in 20 011 of PBS for 30 s at 10,000 rpm in a VirTis homogenizer (VirTis Co. Inc., 
Gardiner, N.Y.). Two hundred microliters of the serial twofold dilutions of each homogenate was 
plated on SDA plates. The remainder of the homogenate, together with an equal volume of 
double-strength SDA, was mixed and poured into petri dishes. All plates were incubated for 48 
hat 37"C 
Gastrointestinal colonization in immunocompetent mice. Gastrointestinal colonization 
was established by pretreating mice for five days with cefradine (1 glUter, Velosef 250; Bristol 
Myers-Squibb, Woerden, The Netherlands). Cefradine was added to their drinking water 
throughout the experiment. Inoculation with 1.107 CFU of C. albicans was performed by gastric 
intubation. Feces were collected and cultured, at 2-day intervals. The mice were sacrificed 8 days 
after inoculation with C. afbicans. Blood was sampled by cardiac puncture and collected into 
EDTA-coated tubes. One hundred microliters of blood was directly subcultured on SDA plates, 
and 100 pi of whole blood was used for DNA extraction. Kidneys, lungs, liver, and spleen as well 
as stomach and gastrointestinal tract were removed, homogenized, and cultured as described 
above. 
peR sample preparation. For Candida DNA extraction from blood we used a method 
modified from Buchman et al. (3). Briefly, 0.1 011 of lysis buffer (0.32 M sucrose, 10 mM Tris-HCI 
[pH 7.5J, 5 mM MgCi" 1% Triton X-100) was added to 0.1 011 of whole blood. After lysis, cell 
debris and Candida yeast cells were pelleted by centrifugation (Eppendorf; Merck, Amsterdam, 
The Netherlands) at 16,000 x g for 5 min. The pellet was resuspended in 0.2 011 of lysis buffer. 
To remove free, non-yeast cell DNA, 7 pi of DNase (10 mg/ml, Boehringer GmbH, Mannheim, 
Germany) was added and the samples were incubated at 37°C for 1 h. After centrifugation at 
16,000 x g for 5 min, pellets were resuspended in 0.2 ml of TEG buffer (50 mM glucose, 25 mM 
Tris-HCI [pH 8.0], 10 mM EDTA) containing 1.5 III Lyticase (900 Ufml; Sigma Chemical Co., St. 
Louise. Mo.) and incubated for a further 1 h at 37°C Subsequently, 3.0 III of pronase (15 mglml; 
Boehringer GmbH) and 10 III of 10% sodium dodecyl sulfate (50S) were added and further 
incubated for 1 h at 3rc. DNA extraction and purification was realized by using Prep-A-gene 
DNA Matrix according to the instructions of the manufacturer (Bio-Rad Laboratories, Richmond, 
Calif.). The matrix was eluted with 40 III of TE buffer (10 mM Tris-HCi [pH 8.0], and 1 mM 
EDTA). 
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Filter tips .(Biozym, landgraaf, The Netherlands) were used throughout the whole isolation 
procedure to avoid contamination. 
Primers and PCR protocol. PCR was performed on 10 pi of the DNA samples, which 
corresponded to 25 pi of the original blood sample. The following primer set, generating a 180-
bp fragment spanning the V4 region of the small subunit rRNA gene, was used: 532 (5'-
TATIAMGTIGTIGCAG-3') and 651 (5'-CCTGCTTIGMCACTCTMTTI-3') (13). PCR was 
performed in 100 pi of PCR solution containing 50 mM KCI, 10 mM Tris HCI (pH 8.3), 2.5 mM 
MgCl" 200 pM of (each) dNTP, 50 pmol of each primer, 0.1 mg of gelatin per ml, 1 U of Taq 
DNA polymerase (Promega, leiden, the Netherlands) and 10 pi sample specimen. The reaction 
mixture was overlaid with 100 pi of mineral oil (Sigma) to prevent evaporation and was 
preincubated for 5 min at 94°C for DNA denaturation. Forty cycles of amplification were 
performed with a peR processor (Biomed Gmbh, Theres, Germany). Each cycle consisted of a 
denaturation step at 94°C for 1 min, a primer-annealing step at 52°C for 1.5 min and a chain-
elongation step at 74°C for 1 min. After 40 cycles, a temperature-delay step of 5 min at 74°C 
completed elongation. Thirty microliters of the amplified peR product was analyzed byagarose 
(1.5% vvtlvol) gel electrophoresis. 
Southern blot analysis of PCR products. DNA was transferred from agarose to Hybond 
Plus nylon filters (Amersham International, pic, Amersham, United Kingdom) by overnight 
diffusion blotting in 0.4 N NaOH. The PCR products were analyzed with the c. albicans-specific 
probe (5'-GTAGCCATTIATGGCGMCC-3') (13). The membranes were preincubated at 37°C in 
a hybridization solution (5x SSC [lx SSC is 0.15 M NaCI plus 0.D15 M sodium citrate], lx 
Denhardt's solution) for 1 h. Hybridization occurred overnight at 37°C with 20 pmol of T4 
polynucleotide kinase (Life Technologies, ltd., Renfrewshire, Scotland) [y_32PIATP (3,000 Ci/mmoli 
Amersham)-Iabelled oligonucleotide probe. The filters were washed once for 15 min at 37°C and 
once for 15 min at 55°C with 2 x SSC, 0.1 % (wtIvol) 50S. Autoradiography was performed with 
Kodak Royal X-omat film and a 3.S-h exposure time. 
RESULTS. 
PCR sensitivity. In order to develop a test with a better sensitivity than blood 
culture, special effort was put into determining the method of DNA extraction and into 
creating optimal storage conditions for the blood samples. As a guideline for the DNA 
extraction, the method described by Buchman et al. (3) was used. An essential step in the 
DNA extraction procedure proved to be the digestion of non-yeast DNA by DNase 
pretreatment. figure I shows the results of making a 1 o-fold dilution series of C. albicans 
in whole sheep blood and performing the DNA extraction with and without DNase 
pretreatment. By application of DNase pretreatment we were able to detect 10 to 15 cells 
of C. albicans per 100 pi of whole blood. Leaving out the DNase treatment, only 150 to 
200 cells of C. albicans per 100 pi could be detected, thus reducing the sensitivity of the 
PCR assay at least lO-fold. 
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Figure 1. Southern blot analysis of C. albicans peR products in whole sheep blood with (Ai and 
without (8) DNase pretreatment. Lanes: 1 through 5, C. albicans cells spiked at 2,300, 230, 115, 
23, and a (negative control) per 100 pI of whole blood, respectively. 
Before starting the in vivo experiments, several conditions were studied with 
regards to the storage of blood samples for PCR analysis. Several blood samples were 
spiked with a lO-fold dilution series of C. albicans in whole sheep blood, and the 
following three procedures were tested: (i) direct extraction by the standard procedure, 
(ii) partial processing of the samples up to the pronase treatment step and subsequently 
completion of the rest of the standard protocol 1 week later after the samples had been 
kept at -20°C, and (iii) freezing the samples at -20°C for 1 week and subsequent 
extracting DNA by the standard protocol. We found that direct extraction or partial 
processing incurs no loss in reproducibility or sensitivity. However/ freezing the blood 
samples at -20°C for 1 week prior to DNA processing was associated with some loss of 
reproducibility and sensitivity of the PCR assay (Fig. 2). We therefore decided to routinely 
process the blood samples obtained in the in vivo experiments with the two-stage 
extraction procedure, i.e., procedure (ii), so that all samples belonging to one in vivo 
experiment, could be processed in a single PCR. 
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Figure 2. Sensitivity and reproducibility results of the C. albicans peR assay conducted with 
whole sheep blood processed by three different procedures: direct testing after DNA extraction 
by the standard procedure (A), partial processing of the samples up to the pronase treatment step 
and subsequent completion of the rest of the standard protocol 1 week later after the samples 
had been kept at -20°C (8), and freezing the samples at -20°C for 1 week and subsequent 
extraction and testing according to the standard protocol (e). Lanes: 1 through 5, C. albicans 
DNA (rom 3,000, 300, 150, 30, and 10 cells per 100 pI o( whole blood, respectively; lanes 6 
and 7 are negative controls. Lane 6, 100 pi of processed blood sample; lane 7, 100 pi of sterile 
PBS (both lanes without spiked Candida cells). 
Systemically infeded mice. To test the sensitivity and in vivo accuracy of the 
Candida PCR assay, we used an induced systemic C. albicans infection in mice with 
cyclophosphamide-induced neutropenia. Since cyclophosphamide is metabolized in the 
liver into metabolites which actively cross-link DNA chains, control experiments were 
performed to check whether blood containing active cyclophosphamide metabolites 
would interfere with the PCR. Therefore, purified C. albicans DNA was added to blood, 
collected from mice 1 and 6 hours after they had received intraperitoneal 
cyclophosphamide, and incubated at 3rc. At 15, 30 and 60 min of incubation, samples 
were taken and the DNA was extracted and assayed by PCR. From these experiments it 
was concluded that active cyclophosphamide metabolites did not interfere with the 
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Candida PCR assay on whole blood (data not shown). 
After the mice were i.v. challenged with 104 CFU of C. albicans the mean number 
of CFU per organ increased (kidney) or remained more or less constant (lung, liver, and 
spleen) over the course of the experiment (Fig. 3). The infection model is reproducible 
since the number of CFU per organ remained in the same order of magnitude (Fig. 3). 
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Figure 3. Progression of systemic infection in neutropenic mice, expressed as the mean number 
of CFU of C. albicans in the kidney (+), spleen (0), lung (.) and liver (. ), obtained from three 
separate in vivo experiments. In each experiment, 21 mice were inoculated with 104 CFU of C. 
albicans and three mice were sacrificed at I, 6, 24, 48, 72, 96, and 144 h after i. v. inoculation. 
Each symbol represents the geometric mean, the standard deviation, for three experiments using 
three mice each (n = 9). 
The results of the blood cultures and PCR are given in Table 1. Blood culture 
results varied considerably and showed CFU counts ranging from 0 to 45 CFU per 100 
pi of blood. Early after the onset of the infection as well as at 72 h into the infection, 
blood cultures tended to yield higher numbers of CFU. At 24 and 48 h, the CFU counts 
were often lower than at 1 and 72 h. In Figure 4 PCR results of the blood samples, from 
each mouse, from experiment 1 and 3, indicate that with progression of the infection 
more DNA targets became available for amplification. However, this increase in PCR 
signal did not correlate with the number of CFU of C. albicans cultured from the same 
blood sample (Table 1). This difference in the sensitivity of the PCR versus blood culture 
was scored at each sampling moment (Table 1). PCR was more often positive at 48 and 
72 h and has, therefore, a better sensitivity than blood culture. In only one blood sample 
C. albicans was cultured (1 CFU per 100 pl) but no PCR signal could be obtained 
(experiment 2; 24 h). 
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Figure 4. Southern blot analysis of Candida PCR amplificates from the blood of each mouse with 
systemic candidiasis sacrificed at the indicated time intervals. Lanes: 1 to 3, 4 to 6, 7 to 9, 10 
to 12, 13 to 15, 16 and 17, and 18 represents mice sacrificed at 1, 6, 24, 48, 72, 96, and 144 
h after i, v. inoculation, respectively. +, positive controls; -, negative controls (processed blood 
of uninfected mice), The top gel corresponds to experiment I, and the bottom gel corresponds 
to experiment 3 (Table 1). 
Gastrointestinal colonization of mice. From the previous results we concluded 
that the PCR assay may be more sensitive than blood culture for the detection of systemic 
C. albicans infection. To gain insight into the ability of the PCR assay to accurately 
discriminate between colonization and invasive candidiasis, a model for gastrointestinal-
tract C. albicans colonization in mice was established. 
After inoculation of six mice with 10' CFU of C. albicans, feces were cultured 
from the animals at days 2, 4 and 6. Feces cultures grew C. albicans in a yield of 14 to 
1,500 CFU per mg of feces. In contrast, feces samples of cefradine-treated mice before 
inoculation were all negative for C. albicans. 
Eight days after inoculation with C. albicans mice were sacrificed and several 
organs were cultured. The stomach and gastrointestinal tract grew C. albicans in each 
case. In contrast kidneys, liver, lung, and spleen were always sterile. Cultures of blood 
samples obtained at day 8 via cardiac puncture were all culture negative as were the 
results of PCR on the same blood samples (data not shown). 
Table 1. Individual blood culture and peR results obtained from neutropenic mice sacrificed at the indicated times after 
i. v. inoculation with C. albicans, in each of three separate experiments 
Resultsa for expt: Sensitivity (%}b 
Time (h) 2 
No. of CFUc PCR' No. of CFU PCR 
39,7,6 +, +, + 9,12,2 +,+,+ 
6 6, 1, 3 +,+,+ 3,3,4 +, +, + 
24 1,0,0 +, +,+ 3, 1, 1 +, w, + 
48 2,0,0 +, +, + 0,0,0 +, +,-
72 0,0,0 +, +, + 27,15,13 +, +, + 
96 0, 0, #" +, +,# #,#, # #, #, # 
144 1, #, # +,#, # #, #, # #, #, # 
J Each result is for a single mouse <three mice per experiment). 
b Sensitivities were determined presuming all samples should be culture and PCR positive. 
c Per 100,£11 of blood collected in EDTA-coated tubes. 
d Using 2S,u1 of pretreated blood. 
<' Mouse died prematurely. 
3 Culture PCR 
No. of CFU PCR 
6,3,5 +,+,+ 100 100 
0,3,0 +, +, + 78 100 
8,4,0 +,+,+ 67 89 
20,7,1 +, +, + 44 89 
34,45,14 +, +, + 67 100 
5,1, # +, +,# 50 100 
#, #, # #, #, # 100 100 
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DISCUSSION. 
Several previous studies have described the development of specific PCR 
techniques for the detection of C. albicans and assessed its sensitivity in vitro and in vivo. 
Buchman et al. (3), Miyakawa et al. (10) and Holmes et al. (5) were able to detect ± 10 
Candida cells per 100 pi of 1 ml of blood. Buchman et al. (3), Kahn et al. (8) and 
Crampin and Matthews (4) were able to detect C. albicans not only in blood samples but 
also in other clinical specimens including sputum and urine. However, since these 
specimens were usually positive by conventional culture as well, the PCR did not 
contribute much to the actual diagnostic sensitivity. Furthermore, most assays described 
were too specific, in the sense that they were designed to detect C. albicans only. 
The PCR method described in this paper uses primers aimed at the multicopy gene 
coding for the small subunit rRNA and results in a 180-bp fragment. The advantage is that 
with the use of a species-specific probe both yeast genus- and species-specific information 
can be obtained by a single PCR (13). To study the merits of this PCR method, its 
sensitivity and specificity were tested in neutropenic mice with an induced systemic 
infection and in immunocompetent mice with gastrointestinal colonization only. The 
sensitivity with this PCR is on the order of 10 to 15 C. albicans cells per 100 pi of spiked 
blood, which is comparable with the results of other methods (3, 5, 10). We also 
demonstrated that the digestion of non-yeast DNA is essential for obtaining such levels 
of sensitivity. Omitting the DNase pretreatment procedure reduces the sensitivity by at 
least a factor of 10 and may also result in aspecific amplificates, as was shown in the 
paper of Crampin and Matthews (4), although they used another primer set aimed at the 
HSP 90 protein. Other parameters for increasing the sensitivity, like concentrations of 
MgCI" dNTP's and primers, have been optimized as described previously (13). 
Furthermore, it has been demonstrated that the storage conditions of blood 
samples influences the sensitivity and reproducibility of the PCR assay. We did not 
succeed in clarifying the negative effect of freezing, since by microscopy Candida cells 
looked intact and were still viable when checked by culture. Possibly, the Candida cells 
become fragile during freezing and thawing such that the DNase, during the pretreatment 
step, can reach some of the essential Candida target DNA, thereby reducing the 
sensitivity and reproducibility of the PCR assay. 
From the neutropenic mice with a systemic Candida infection, a higher percentage 
of positive test results was obtained by PCR than was obtained by conventional blood 
culture. Kahn (8) also demonstrated positive PCR results in a candidemic murine model. 
However, in that study, blood samples obtained from five mice were pooled and were 
always positive by culture. In contrast, we demonstrated positive PCR results from blood 
samples of individual mice, some of which had sterile blood cultures at the same time. 
Positive PCR results may be due to the amplification of circulating nonviable, Candida 
cells, e.g., those within phagocytic cells. It is this aspect of the PCR technique which 
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makes the method more sensitive than blood culture. Makimura et al. (9) also obtained 
positive PCR results from culture-positive as well as from culture-negative blood samples 
of mice infected by C. albicans. However, for DNA extraction they used a volume of 
blood which was twice that used for culture. Since the sensitivity of an assay is 
influenced by the volume tested, their results should be interpreted with great care. In 
our study we actually applied only 25 pi of blood for PCR compared to 100 pi for blood 
culture. Thus, the sensitivity of our PCR may be further increased by using more target 
DNA in the final reaction. Despite the sensitivity of the PCR, PCR results obtained from 
blood samples of gastrointestinally colonized mice were always negative. This particular 
aspect makes this PCR useful since it is able to discriminate between invasive candidiasis 
and colonization. The negative findings with the colonized model also underline the 
target specificity of this PCR method, in that no false positive results were obtained 
because of existing normal mouse bacterial flora. 
Although the PCR assay of blood samples of mice with systemic candidiasis was 
not designed to give quantitative information, the intensity of the hybridization signal 
clearly increased with progression of the infection. These findings suggest a correlation 
between the PCR results and the degree of dissemination of infection and make the 
technique possibly valuable as a clinical monitoring assay. 
In conclusion, PCR with primers directed against the small subunit rRNA gene in 
combination with the C. albicans-specific probe provided a sensitive and specific assay 
for detecting Candida DNA in whole blood. This PCR method promises to be more 
sensitive than blood cultures and may be an adequate technique in the early detection 
and follow-up of invasive candidiasis. Besides being sensitive, this PCR is specific, since 
PCR results obtained from blood samples of gastrointestinally colonized mice were 
negative; therefore, this PCR is diagnostically useful. Another positive diagnostic 
contribution is the relative speed of the PCR, since results are achieved within two days, 
whereas conventional blood cultures take 1 to 7 days or even longer. The true clinical 
relevance and utility of this test has to be proven in a prospective clinical study in which 
conventional blood cultures are evaluated in relation to PCR. 
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ABSTRACT 
When a diagnosis invasive candidiasis has been made, Irealmenl with loxic 
fungicidal agents is inevilable. The crucial decision of when 10 slop such Irealmenl is 
difficuillo make, because cullures are of len negalive despile ongoing invasive candidiasis 
and can Iherefore nol be used as a reliable parameler of effeclive Iherapy. In Ihe presenl 
sludy, Ihe use of PCR in moniloring Ihe Iherapeulic efficacy of anlifungallrealmenl wilh 
liposomal ampholericin B was evalualed by using neulropenic mice with syslemic 
candidiasis. Blood cui lures of infecled mice Irealed wilh differenl doses of liposomal 
ampholericin B were only posilive allhe early onsel of Ihe infeclion process and became 
slerile wilhin 3 days; Ihis was Irue even wilh mice Irealed wilh 1 mg of liposomal 
ampholericin B per kg of bodyweighllhal experienced a relapsed infeclion 14 days laler. 
A significanl correlalion belween presence of C. albicans CFU in Ihe kidneys and PCR 
resulls oblained with blood was demonslraled. Thus PCR resulls oblained wilh blood 
samples correlaled well wilh Ihe Iherapeulic efficacy of antifungallrealmen!. 
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INTRODUCTION 
Invasive candidiasis is an important cause of mortality and morbidity, particularly 
in immunocompromised patients. Unfortunately, efficient diagnosis is hampered by the 
lack of clinical parameters that can be used to recognize invasive candidiasis. A 
combination of microbiological, histological, and serological results may sometimes 
contribute to the diagnosis, but these tests are not 100% sensitive and specific (3). 
Recently, non-culture-dependentassays such as the polymerase chain reaction (PCR) have 
gained increasing importance in the rapid diagnosis of infections in patients at risk (10). 
The contribution of PCR assays in the diagnosis of fungal infections has now been 
demonstrated with a wide variety of clinical specimens including blood, serum, 
respiratory secretions, urine, peritoneal fluid, and cerebrospinal fluid (2, 4-7, 9, 12). It has 
been demonstrated that peR has a better sensitivity than blood cultures in detecting 
Candida albicans infection in persistently neutropenic mice (14). Apart from helping to 
diagnose invasive candidiasis, an ideal assay should also help in monitoring the response 
to treatment and thus in determining the duration of therapy. Since toxic fungicidal agents 
are used, achieving accurate estimates of the time at which treatment can be stopped is 
clinically highly relevant. In the present study, we evaluated the use of peR in monitoring 
the response to antifungal treatment with a liposomal formulation of amphotericin S 
(AmS) (AmSisome®) in neutropenic mice with systemic candidiasis. peR results were 
compared with blood culture results at several time points during the course of the 
infection. 
MATERIALS AND METHODS 
Animals and C. albicans strain. Specific-pathogen-free, 11- to 13-week-old female BALBIc 
mice weighing 22 ± 1.3 g were used (lffa Credo, L'Arbresle, France). C. albicaos (ATCC 44858) 
was used throughout all the experiments. The yeast was stored at ~80°C in Todd~Hewitt broth 
(Difco laboratories, Detroit, Mich.) containing 10% (vol/voll glycerol. Stationary-grmvth-phase 
cultures were obtained after incubation of C. a/bicans in Sabouraud maltose broth (Diko 
Laboratories) for 24 h at 37°C. Yeast cells were washed in phosphate-buffered saline (PBS), 
counted in a hemocytometer, and adjusted to 5 x 104 cells per ml in PBS. 
Antifungal agent. AmBisome®, ArnB, encapsulated in small unilamellarvesicles consisting 
of hydrogenated soybean phosphatidylcholine, cholesterol, and distearoylphosphatidylglycerol 
in a molar ratio of 2:1:0.8, was kindly provided by Vestar Inc. (San Pi mas, Calif., USA) as a 
lyophilized preparation. The powder was reconstituted with distilled water at 65°C according to 
the manufacturer's instructions to give a liposomal suspension containing 4 g of AmB per liter and 
35 g of lipid per liter. 
Systemic infection in neutropenic mice. A model of invasive candidiasis in persistently 
neutropenic mice as previously described, was used (15). Briefly, neutropenia was induced by 
intraperitoneal administration of cyclophosphamide (Sigma Chemical Co., St. louis, Mo.) at 100 
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mgfkg of body weight 4 days prior to inoculation with C. albicans, followed by additional doses 
of 75 mglkg on the day of inoculation and at 3-day intervals during the course of infection (15). 
This treatment resulted in persistent granulocytopenia of < 100 granulocytes per pi of blood from 
the time of inoculation with C. albicans up to termination of the studies. 
In each experiment, 19 neutropenic mice were infected by inoculation of 200 pi of 5 x 
10' C. albicans CFU!ml in the tail vein. AmB was administered intravenously (i.v.) for 4 
consecutive days at dose of 1, 7, or 14 mglkg of body weight. At 1 h, or 3, 6, 14, 21, and 35 
days after inoculation with C. albicans, groups of 3 to 4 mice were sacrificed and blood was 
collected in EDTA-coated tubes by cardiac puncture_ Of each blood sample, 100 pi was directly 
cultured on Sabouraud dextrose agar (SDA) plates (Oxoid, Basingstoke, England) and incubated 
for 5 days at 37°C. Another 100 pi of blood was used for DNA extraction. 
The kidneys, spleen, liver, and lungs were removed from each mouse and separately 
homogenized in 20 ml of PBS for 30 s at 10,000 rpm in a VirTis homogenizer (VirTis Co. Inc., 
Gardiner, N.Y.). Residual AmB was eliminated from the homogenates by washing the sediment 
after centrifugation three times with PBS. Two hundred microliters of the serial lO-fold dilutions 
of each homogenate was plated on SDA plates. Two milliliters of the homogenate and the 
remainder of the homogenate, together with 18 m[ and an equal volume of double-strength SDA 
respectively, were mixed and poured into petri dishes. All plates were incubated for 48 h at 
3rc. 
PCR sample preparation. For Candida DNA extraction from blood we used a method 
modified from that of Buchman et al. (2, 14). Briefly, 0.1 ml of lysis buffer (0.32 M Sucrose, 10 
mM Tris-HCI [pH 7.5], 5 mM MgCI" 1 % Triton X-100) was added to 0.1 ml of whole blood. 
After lysis, cell debris and Candida cells were pelleted by centrifugation (Eppendorf centrifuge; 
Merck, Amsterdam, The Netherlands) at 16.000 x g for 5 min. The pellet was resuspended in 0.2 
ml of lysis buffer. To remove free, non-yeast cell DNA, 7 pi of DNase (10 mgfml, Boehringer 
Mannheim Gmbh, Mannheim, Germany) was added and the samples were incubated at 37°C 
for 1 h. After centrifugation at 16.000 x g for 5 min, pellets were resuspended in 0.2 ml of TEG 
buffer (50 mM Glucose, 25 mM Tris-HCI (pH 8.0), 10 mM EDTA) containing 1.5 pi of Lyticase 
(900 U!ml, Sigma Chemical Co.) and incubated for a further 1 h at 3rc. Subsequently 3.0 pi 
of pronase (15 mgfml, Boehringer Mannheim) and 10 pi of 10% sodium dodecyl sulfate (50S) 
were added and incubation was continued for 1 h at 37°C, DNA extraction and purification were 
realized by using Prep-A-Gene DNA Matrix according to the instructions of the manufacturer (Bio-
Rad laboratories, Richmond, Calif., USA). The matrix was eluted with 40 pi of TE buffer (10 mM 
Tris-HCI [pH 8.0], and 1 mM EDTA). 
Filter tips (Biozym, landgraaf, The Netherlands) were used throughout the whole isolation 
procedure to avoid contamination. 
Primers and PCR protocol. peR was performed in a 100 pi volume under standard 
conditions with 5 and 10 pi of the DNA samples. The following primer set, generating a 180-bp 
fragment spanning the V4 region of the ssu·rRNA gene, was used: 532 (5'-
TATIAAAGTIGTIGCAG-3') and 651 (5'-CCTGCTTTGMCACTCTMTTT-3') (10). PCR was 
performed in 100 pi of PCR solution, containing 50 mM KCI, 10 mM Tris HCI [pH 8.3], 2.5 mM 
MgCI" 200 pM of each desoxynucleoside triphosphate, 50 pmol of each primer, 0.1 mg of 
gelatin per ml, 1 unit of Tag DNA polymerase (Promega, Leiden, the Netherlands) and 5 or 10 
pi sample specimen., The reaction mixture was overlaid with 100 pi of mineral oil (Sigma) to 
prevent evaporation and was preincubated for 5 min at 94°C for DNA denaturation. Forty cycles 
of amplification were performed with a PCR processor (Biomed Gmbh, Theres, Germany). Each 
cycle consisted of a denaturation step at 94°C for 1 min, a primer annealing step at 52°C for 1.5 
74 Chapter 6 
min, and a chain elongation step at 74°C for 1 min. After 40 cycles a temperature delay step of 
5 min at 74°C completed elongation. A 30-111 volume of the amplified PCR product was analyzed 
by agarose (1.5% wtlvol) gel electrophoresis. 
Southern blot analysis of PCR products. DNA was transferred from agarose to Hybond 
Plus nylon filters (Amersham International, pic, Amersham, United Kingdom) by overnight 
diffusion blotting in 0.4 N NaOH. The PCR products were analyzed with the C. albicans specific 
probe (5'-GTAGCCATTTATGGCGMCC-3') (10). Membranes were pre-incubated at 37°C in a 
hybridization solution (5 x SSC [1 x SSC is 0.15 M NaCI, 0.Q15 M sodium citrate], 1 x 
Denhardt's solution) for 1 h. Hybridization occurred overnight at 37°C with 20 pmol of T, 
polynucleotide kinase (Bethesda Research Laboratories Inc.) and [r-"P]ATP (3000 Cilmmol, 
Amersham Internationl plc.)-Iabelled oligonucleotide probe. The filters were washed 1 x 15 min 
at 37°C and 1 x 15 min at 55°C with 2 x SSC, 0.1 % (wtivol) 50S. Autoradiography was 
performed with Kodak Royal X-Omat film and a 3.5-h exposure time. 
RESULTS 
Optimization of Candida PCR. To rule out an inhibitory effect of residual AmB 
on the PCR assay, blood of mice pretreated with AmB at 17 mg/kg for 4 days was spiked 
with a la-fold dilution series of 2,000 to 2 cells of c. albicans and incubated for 30 min 
at 37°C, and tested in the peR assay. No difference in the lower limit of detection was 
found between blood of treated and untreated mice (data not shown). In a previous study 
we used 10 pi of DNA sample in the final peR (10). In the present study, we tried to 
improve the sensitivity of the assay by adding several volumes of extracted DNA obtained 
from blood samples spiked with different numbers of yeast cells. No significant 
differences were obtained by using 5 or 10 pi of extracted DNA sample in this in vitro 
experiment. However, the sensitivity of the peR decreased lOa-fold if 15 pi of the same 
DNA sample was used (Fig. 1). We thus decided to use 5 pi as well as 10 pi of DNA 
samples in the current study. 
1 2 3 4" 5 0 1 2 3 4 5 0 1 2 3 4 5 0" 0 + 
figure 1. Southern blot analysis of C. albicans PCR products obtained by amplification of 
different volumes of processed blood samples spiked with 2,000, 200, 20, 10, 2, and ° (negative 
control (-J) C. albicans cells per 100 111 of blood. lanes 1 - 5; represent the dilution series 
obtained by amplification of 5, 10, and 15111 of processed blood (lane sets from left to right); +, 
positive control (whole blood spiked with C. albicans cells). 
PCR to monitor therapy of candidiasis 75 
PCR monitoring of invasive candidiasis. After challenge with C. albicans, AmB 
was administered for 4 consecutive days at dose of 1, 7, or 14 mg/kg of body weight. In 
mice treated with 1 mg of AmB per kg an initial drop in CFU per organ in lung, liver, 
and spleen was observed, and then there was an increasing number of CFU per organ 
from 14 to 21 days after inoculation (Fig. 2). Number of CFU in the kidneys, however 
remained stable and increased from 104 at day 14 to 10' at day 35. 
Cultures from lungs, livers, and spleens of mice treated with 7 and 14 mg of AmB 
per kg became sterile within three days of treatment (Fig. 2). In contrast, the number of 
CFU in the kidneys of mice treated with 7 and 14 mg of AmB per kg decreased only 
slowly and cultures became sterile between days 14 and 21 (Fig. 2). 
Eight of nine blood samples taken 1 h after the challenge grew C. albicans (Table 
1). Of the mice treated with 1 mg of AmB per kg, only one had a C. albicans positive 
blood culture for the sample taken 3 days after the challenge. All other blood samples 
taken later in the infection process in all three treatment regimens failed to grow C. 
albicans. 
The PCR results obtained by amplification of 5 pi of target DNA (Fig. 3) of blood 
samples of mice treated with 1 mg of AmB per kg show an initial decrease in PCR 
hybridization signals, which were absent on day 14. However, at day 21 PCR gave 
positive results again (Fig. 3; Table 1). PCR with 10 pi of target DNA actually 
demonstrated that a constant level of target DNA was present in the blood; however, the 
intensity of the hybridization signals of samples taken on day 35 was higher (Fig. 4). 
Mice treated with 7 mg of AmB per kg showed positive PCR results only at 1 h 
and 35 days if 5 pi of target DNA was used. PCR with 10 pi showed a similar profile. 
However, more often a positive PCR result was found between 1 hand 35 days (Fig. 3 
and 4; Table 1). Samples from mice treated with 14 mg of AmB per kg gave several 
positive PCR signals over time if 5 pi was used; however, 5 pi target DNA samples were 
all negative at day 35. If 10 pi was used only negative PCR signals were obtained (data 
not shown). 
A positive correlation between the PCR results obtained by using 10 pi of 
processed sample for all three treatment regimens and the positive kidney cultures of the 
mice was demonstrated (P~0.04; Fisher exact test). No such correlation could be 
demonstrated with the data from PCR with 5 pi of processed blood sample. 
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Figure 2. Progression of systemic infection in neutropenic mice treated with 4 daily doses of 1 
mg of AmB per kg (A); 7 mg of AmB per kg (B); 14 mg of AmB per kg of body weight (C). Data 
are expressed as the mean number ± standard error (error bars) of CFU of C. albicans in the 
kidney (0), spleen (0), lung (_), and liver (.). Data are based on three to four mice. 
Table 1. Blood culture and peR hybridization results in neutropenic mice after i. v. inoculation with C. albicans. 
Time 
1 h 
3d 
6d 
14 d 
21 d 
35 d 
No. of 
CFU b 
0,6,4 
0,93,0 
0,0,0 
0,0,0 
0,0,0,0 
0,0,0 
1 mg Amb/kg 
PCR'" PCR'" 
+,+,+ +,+,+ 
- ,+,- +,+,+ 
- ,+,+ +,+,+ 
- , - -,+,+,+ 
- ,+,+,+ +, -, -,+ 
+,+,+ +,+,+ 
Resu!ts with AmB regimenJ. 
7 mg AmB/kg 14 mg AmB/kg 
No. of No. of 
CFU PCR' PCR" CFU PCR' 
1,1,7 - ,+,+ +,+,+ 8,6,6 +,+,+ 
0,0,0 - , - , - - , - , - 0,0,0 - , - , 
0,0,0 - ,+,- +,+,+ 0,0,0 - , - , -
0,0,0 +, -,- +,+,- 0,0,0 +,+,-
0,0,0,0 +,+, -,- +,+,+,+ 0,0,0 +,+,+ 
0,0,0 +,+,- +,+, - 0,0,0 
PCR" 
- -, 
-
-, 
- -, 
J. Mice were treated with respectively 1, 7, and 14 mg of AmB per kg for 4 days, and sacrificed at indicated interva!; data are from individual animals 
in each of three separate experiments. 
b Data are per 100 ,uL of blood. 
c PCR5 hybridization signals obtained by using 5 p! of processed blood for PCR, + - positive signa!; - - negative signal. 
d peR'o hybridization signals obtained by using 10 p! of processed blood for peR, + - positive signa!i - - negative signal. 
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figure 3. Southern blot analysis of 5 /11 of C. albicans peR products obtained from blood samples 
from mice treated with 1 (top), 7 (middle), 14 (bottom) mg of AmB per kg. Lanes 1 to 3, 4 to 6, 
7 to 9, 10 to 12, 13 to 16, and 17 to 19 represent mice sacrificed at 3 h, and 3,6, 14,21, and 
35 days after i. v. inoculation, respectively. +, positive controls (whole blood spiked with C. 
albicans cells); -, negative controls (= whole blood of uninfected control mice) 
• 2 ;J. " 5 6 1 8 9 10 11 12 13 14 15 It> H 18 19 ..... 
1 ;J. " 5 6 1 8 9 10 11 U U 14 15 It> 11 16 19 .... 
Figure 4. Southern blot analysis of 10 pi of C. albicans PCR products obtained with blood 
samples of mice treated with 1 (top) and 7 (bottom) mg of AmB per kg. Lanes 1 to 3, 4 to 6, 7 
to 9, 10 to 12, 13 to 16, and 17 to 19 represent mice sacrificed at 3 h, and 3, 6, 14, 21, and 35 
days after i. v. inoculation, respectively. + I positive controls (whole blood spiked with C. albicans 
cells),. -, negative controls (whole blood of uninfected control mice). 
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DISCUSSION 
Generally, it takes 2 to 7 days for Candida spp. to grow from patients' specimens. 
Therefore, microbiological culture cannot be regarded as an early diagnostic tool. 
Furthermore, even the best blood culture technique often gives negative results despite 
evidence of systemic infection (1). A breakthrough in diagnostic microbiology has been 
the introduction of the PCR technique for the detection of Candida spp. in several clinical 
specimens (8, 11). In a previous study, we demonstrated that PCR was more sensitive 
than culture in detecting C. albicans in blood from neutropenic mice with invasive 
candidiasis (14). 
Once the diagnosis of invasive candidiasis has been made treatment with toxic 
fungicidal agents is inevitable. The decision of when to stop treatment is even more 
difficult to make, since negative cultures are not always indicative of a therapeutic 
response. Therefore, the aim of the present study was to examine the usefulness of PCR 
as an assay to monitor the response to AmB in neutropenic mice with invasive 
candidiasis. 
Berenguer et al. (1) demonstrated in a clinical setting the existence of a correlation 
between the number of organs infected by Candida spp. and the number of positive 
blood cultures. Our results showed that blood cultures of infected mice treated with three 
different doses of AmB were positive only at the beginning of the treatment and became 
sterile within 3 days, even for mice treated with 1 mg of AmB per kg that experienced 
a relapse of infection after 14 days. On the other hand, a significant correlation between 
the number of CFU in the kidneys and the PCR results was demonstrated. Likewise, 
hybridization signals of the PCR increased with increasing numbers of C. albicans CFU 
in the kidneys of untreated mice (14). This correlation between the number of CFU in the 
kidneys and positivity of the PCR can only be explained by the fact that intact Candida 
cells are still present and detectable by PCR in the peripheral circulation. Since in the 
DNA extraction procedure a DNase treatment step is incorporated before the actual lysis 
of the Candida cells, the possibility that we are detecting circulating C. albicans DNA 
only is ruled out. Blood culture results for the same samples were negative, however, 
probably because of the low level or complete absence of metabolic activity of the 
Candida cells or the inhibitory presence of residual AmB. 
Strong hybridization signals were observed at day 35 with mice that had been 
treated with a regimen of 7 mg of AmB per kg for 4 days, suggesting a relapse of the 
infection despite negative cultures from the kidneys, livers, lungs, and spleens at that 
moment. This hypothesis could not be further analyzed since we did not evaluate the 
progression of infection beyond day 35. Samples obtained with a regimen of 14 mg of 
AmB per kg showed negative PCR results at day 35. This regimen might thus be more 
effective than 7 mg of AmB per kg implicating that mice treated with the 7 mg of AmB 
per kg had not completely cleared the Candida cells. On the other hand, false-positive 
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signals are not a problem with this PCR since multiple blood samples from 
gastrointestinally colonized mice (14) and normal control mice were all negative by PCR. 
PCR with 5 pi of processed target DNA was less sensitive than PCR with 10 pi of 
target DNA of blood samples in the in vivo experiment for mice treated with 1 or 7 mg 
of AmB per kg, indicating that more target DNA increases the sensitivity of the PCR 
assay. Application of 15 pi of processed target DNA in the PCR, however, caused false 
negative results, probably due to inhibitory factors present in the blood samples. For the 
same reason no hybridization signals were obtained by using 10 pi of target DNA of 
blood samples of mice treated with 14 mg of AmB per kg, whereas the same samples 
were PCR positive if 5 pi was used. It indicates the narrow balance between target DNA 
and inhibitory factors influencing the outcome of the PCR. Therefore, to exclude false· 
negative PCR results it may be necessary to use routinely several concentrations of target 
DNA in the PCR assay. This limitation in sensitivity of the PCR might be overcome in the 
near future if rRNA instead of DNA is used, since there is a high copy number of rRNA 
present in each cell. Another advantage of rRNA is that it can be amplified in a 
commercial available nucleic acid sequence-based amplification system, which is faster 
than PCR (13) and whose enzymes are less sensitive to inhibitory factors. The advantage 
of commercial systems is that they are easy to perform and detection formats are less 
laborious, which makes the introduction of these techniques into all microbiology 
laboratories possible. 
We conclude that in this neutropenic murine model of invasive candidiasis, PCR 
results correlated well with the response to the therapy administered. PCR is much better 
in this respect than routine blood cultures. However, before this assay can be used as 
universal monitoring tool, PCR needs to be further evaluated in this or other animal 
models and in a clinical setting as well. 
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ABSTRACT 
Passive transfer of heterologous rabbit antibodies (IRS) directed against a crude 
Candida albicans extract and hOOlologous Olice anti-enolase antibodies (lMS) were 
adOlinistered in a non-acute but lethal systeOlic Candida Olodel in mice. Protection could 
only be demonstrated by repeated administration of homologous as well as heterologous 
immunesera. The protective effect was not due to non-specific, heat-labile, serum factors 
since fractionated anti-cytoplasmic rabbit immunoglobulins gave also a decreased 
mortality rate. These findings could not be ascribed to enhanced opsonization as 
observed in in vitro opsonization experiments using peritoneal macrophage monolayers. 
In conclusion anti-enolase antibodies are protective against lethal C. albicans infections. 
The protection was not due to enhanced initial clearance of viable C. albicans from the 
internal organs, but was presumably the result of as yet unknown effects of antibodies 
occurring later in the infectious process. 
INTRODUCTION 
Candidiasis represents a spectrum of diseases ranging from colonization of the skin 
or mucous membranes to severe and often fatal disseminated disease. Consequently, it 
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is to be expected that a variety of host immune mechanisms interact in the response to 
Candida albicans. There is now a body of evidence showing that cellular elements 
including the neutrophil, the helper T-Iymphocyte and the monocyte-macrophage play 
an important role in the defense against fungal infections (1, 5, 6, 8, 28). In contrast, 
evidence pertaining to antibody-mediated defense against candidiasis is contradictory and, 
consequently, its role in the pathogenesis of Candida infections is poorly understood. 
Maiti et aI., (12) gathered indirect evidence supporting a role for specific antibodies in 
protection against Candida infections in mice. Several authors have failed to demonstrate 
a protective role of antibodies in passive immunization experiments (2,7), whereas others 
succeeded in demonstrating direct protective effects by transfer of hyperimmune serum 
in mice (13, 17, 19). Some authors have found a protective effect only after vaccination 
with viable C. albicans cells (4, 29). 
No overall conclusion can, thus, be drawn at this time about specific antibody 
protection against candidiasis partly because different treatment schedules of immune sera 
directed toward various antigenic determinants have been used. Also, experiments were 
performed in different animal models of invasive infection. 
In the present study, we evaluated the protective capacities of antibodies directed 
against the immunodominant enolase antigen of C. albicans, and compared its activity 
to that of antibodies directed against a crude C. albicans antigen extract. A non-acute but 
lethal systemic candidiasis mouse model was chosen because it was deemed to be more 
relevant clinically compared to previously published, more acute, lethal infection models. 
Furthermore, in vitro phagocytosis and killing of C. albicans by macrophage monolayers 
were studied. 
MATERIALS AND METHODS. 
Candida strains. Throughout all experiments strain C. albicans ATeC 44858 was used. 
For preparation of the crude antigen extract and of the purified enolase antigen C. albicans CBS 
5982 serotype A (Centraal Bureau voar Schimmelcultures, Delft, The Netherlands) was used. 
Preparation of anti-cytoplasmic immunoglobulins. Antisera were obtained by immunizing 
New Zealand White rabbits, with a crude C. albicans antigen extract, prepared as described 
elsewhere (9). The animals were injected subcutaneously with 12 mg of crude antigen in Ribi 
adjuvant (Ribi Immunochem, Research, Inc, Montana USA). The antibodies directed against the 
crude antigen determinants were monitored by ELISA using the crude antigen. This polyclonai 
polyspecific antiserum was pooled and kept frozen at -80°C, Antibodies directed toward mann an 
were evaluated by counterimmunoelectrophoresis (CIE) and crossimmunoelectrophoresis (XIE), 
techniques which have previously been described (24). 
Immunoglobulin fractionation. Fractionation of immunoglobulins from rabbit sera was 
performed by ammonium sulphate precipitation at 4°c' Ten ml of serum, diluted with an equal 
volume of 10 mM Iris in 0.9% Nael (pH 7.6), was brought to 50% saturation by adding a 
saturated solution of (NH4)2S04' After 30 min at room temperature the suspension was centrifuged 
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at 1,700 x g for 15 min. The pellet was dissolved in 0.9% NaCi and brought to 40% saturation 
by adding a saturated solution of (NH",hS04' Again the solution was left at room temperature for 
30 min and centrifuged at 1,700 x g for 15 min. This procedure was repeated for 33% saturation. 
The pellet was dissolved in 5 ml sterile phosphate-buffered saline (P8S) and dialysed against 
sterile PBS overnight. The titer of anti-Candida antibodies in this immunoglobulin fraction was 
equal to the titer of anti-Candida antibodies of the initial serum, as determined by ELISA. The 
immunoglobulin fraction of immune rabbit serum (IRS) will be designated as IglRS and the 
immunoglobulin fraction of normal rabbit serum (NRS) as IgNRS. 
Preparation of anti·enolase immunoglobulins. Antisera to enolase were raised in BAlBJe 
mice (lffaCredo, l'Arbresle, France) by repeated immunization with purified enolase. Purification 
of C. albicans enolase has been described previously (25). Mice were repeatedly injected 
subcutaneously with 50 Jig of purified enolase in Ribi adjuvant (Ribi Immunochem). Anti-enolase 
antibody levels were monitored by ELISA (25) using enolase as the antigen. This polyclonal 
monospecific anti-enolase antiserum from several mice was pooled and stored at -80°C. 
Specificity of the anti-enolase antibodies was determined by Western blotting using the crude 
antigen extract of C. afbicans. Procedures for gel electrophoresis and immunoblotting were similar 
to those used in previous studies (21), 
Preparation of a monoclonal antibody (MAR) against mannan. Immunization of 14-week-
old BALB/c mice (lffa Credo) was performed with 500llg of crude antigen emulsified in an equal 
amount of complete freund's adjuvant (0.1 mil (Life Technologies B.V., Breda, The Netherlands) 
as described by Mirza et a!. (15). for MAB production the draining lymph nodes were removed 
and pooled for fusion with the mouse myeloma cell line SP 2/0, as described by Dllert et a!. (lB). 
From one done ascites was produced and characterized by immunoblotting, CIE, and XIE. Ascites 
was dialysed against sterile PBS and diluted four times in sterile PBS before use. The MAB is an 
IgG class antibody, and will be denoted as 18Cll. 
ELISA to determine anti-crude antigen antibodies. Highly activated polystyrene microtiter 
plates (Nunc Immunoplate Maxisorp f96) were coated with 0.3 Ilg of crude antigen in 100 III 
coating buffer (0.13 M sodium carbonate and 0.03 M hydrogenated sodium carbonate [pH 9.6J) 
per well and were subsequently incubated overnight at 4°C. The plates were washed twice with 
200 III ofTBS-block (0.01 M Tris, 0.15 M NaCi [pH 7.6], 0.1 % gelatin) per well and were then 
incubated with 200 III of TBS block per well at 37°C for 2 h. The plates were then drained. 
Immune sera or the immunoglobulin fractions were diluted twofold in TSS (0.01 M Tris, 0.15 M 
NaCI [pH 7.6]) starting at a dilution of 1 :50. A total of 50 III of each serum or immunoglobulin 
fraction was added to each well, and plates were subsequently incubated at 37°C for 60 min. 
After three cycles of washing with TBSt (lBS with 0.04% [wtlvolJ gelatin and 0.05% [vollvolJ 
Tween 20), 50 III of an alkaline phosphatase-labelled goat anti-rabbit IgG conjugate (diluted 
1: 1,000 in TBSt [Sigma Chemical Co., St. Louis, Mo.]) was added to each well; this was followed 
by incubation for 1 h at 3rc. A 100 .ul volume of acid enzyme substrate solution (9.7% 
diethanolamine, 3 mM NaN" 5mM MgCI,.6H,o, 1 mglml p-nitrophenylphosphate [SigmaJI was 
added after three cycles of washing with TBSt, and the plates were incubated at 37°C in the dark. 
Color development was stopped after 30 min of incubation by adding 100 III of 3 M NaDH to 
each well. The optical densities at 405 nm were determined by using an automated plate reader 
(Bio-Tek Instruments, Inc, Winooski, Vt.). 
Protective role of various immune sera and Ig fractions in mice. Four hours before mice 
were infected by intravenous (Lv.) inoculation of 3 x 105 CFU of C. afbicans into the tail vein 
(27), mice were intraperitoneal (Lp.) inoculated with 0.4 ml immune rabbit serum (IRS) or 
immune mouse serum (lMS) or with IgIRS. Additional doses of 0.3 ml of sera were given at 6, 
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12 and 18 days after infection. Normal rabbit serum (NRS) or normal mouse serum (NMS) or 
MAB l8Cl1 or PBS served as negative controls, as indicated. 
At 50 days after infection, surviving mice were sacrificed, and their kidneys, lungs, liver, 
and spleen quantitatively cultured for C. albicans (27) on Sabouraud dextrose agar (OxQ"id, 
Basingstoke, England). 
Macrophage monolayers. For macrophages monolayers a modified method of van Etten 
et aI., (26) was used. Briefly, macrophages were obtained from peritoneal cavities of 12~ to 13-
week-old specific·pathogen·free BALB/C mice (lffa Credo). The macrophages were washed twice 
in Dulbecea modified Eagle medium (Flow Laboratories, Irvine, Scotland) supplemented with 1 % 
glutamine. Monolayers of peritoneal macrophages were cultured at 37°C on chamber slides (Lab-
Tek, Bayer, The Netherlands) under a fully humidified atmosphere of 7.5% CO2 in air in culture 
medium containing Dulbecco modified Eagle medium with 5% inactivated fetal bovine serum 
(FBS; Hy·Clone, Logan, Utah). After the first 2 h of incubation, fresh culture medium was added 
to the monolayer, and the macrophages were incubated for 24 h. After this incubation period, 
preopsonized C. albicans cells were added to the monolayers, resulting in a C. albicans-to-
macrophage ratio of 10: 1. C. albicans was preopsonized by incubation of a washed stationary-
growth-phase suspension with 10% of indicated sera or immunoglobulin fractions under 
continuous rotation at 8 rpm for 15 min at 37°C, and subsequent washing the yeast twice in PBS. 
After a 5 or 10 min uptake period, the non-ingested yeasts were removed by washing the 
monolayer three times with cold PBS. The monolayer was fixed in methanol and stained with 
May-Grunwald-Giemsa, after removal of the plastic chamber from the slide. The uptake of C. 
afbicans was determined microscopically! and expressed as percentage of phagocytosing 
macrophages and the average number of Candida cells per macrophage. Intracellular killing was 
performed as described by van Etten et al. (26), and determined after a 5 and 10 min uptake 
period. 
Statistical analysis. Statistical evaluation of the differences in the survival curves between 
serum-treated, immunoglobulin-treated and PBS-treated groups was performed by using the log 
rank test. This test examines the decrease in survival with time as well as the eventual percentage 
of survival. The Kruskal-Wallis test was used for evaluation of the differences in the percentage 
of phagocytosis of the in vitro assays between the various opsonized C. albicans cells. 
RESULTS 
Characterization of raised immune sera. Characterization of the immune sera was 
performed by Western blotting, CIE, and XIE techniques. The IMS reacted as a single 
band in the immunoblot, and IRS reacted with multiple antigenic determinants of 20 to 
90 kDa including the enolase antigen (Fig. 1). IRS did not react with mannan as was 
found by CIE and XIE by using the purified mannan as antigen (data not shown). The 
MAB 18Cll did not recognize any protein by immunoblotting, it only reacted with 
mannan as demonstrated by XIE (data not shown). Titration of the MAB 18Cll by CIE 
resulted in an anti-mannan titer of 1 :256. NRS or NMS did not react with Candida 
antigens as determined by immunoblotting (Fig. 1), ELISA or CIE (data not shown). 
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Figure 1. Western blotting analysis of IMS and IRS using the crude C. albicans antigen as antigen 
extract. Lanes: II Coomassie stained crude antigen; 2, and 3, IMS; 4, IRS; 5, NMS. MW, molecular 
weight markers are indicated on the left. 
Protective role of IRS. Serial blood samples were collected from mice given IRS, 
in order to study the length of time that the anti-Co albicans antibodies remained 
detectable in the blood after immunotransfer. Antibody titers against the crude C. albicans 
antigen and purified enolase were determined (Table 1). It was found that after 
administration of 0.4 ml of IRS to uninfected mice, antibodies directed towards the crude 
antigen decreased over 14 days but did not completely disappear. In sera of mice with 
systemic candidiasis, however, anti-enolase antibodies and anti-crude antigen antibodies 
decreased much more rapidly. Fourteen days after administration, titers decreased under 
the detection limits of the respective assays. In order to maintain a constant level of 
antibodies it was, therefore, decided to give IRS repeatedly at intervals of 6 days. 
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Table 1. Antibody titers, expressed in 00405 values, against the crude antigen and enolase in sera 
of mice after a single transfer of IRS, monitored during 14 days in infected and uninfected mice. 
Crude C. albicans antigen a 
time after uninfected infected 
immunotransfer mice mice 
1 hour 0.605b 0.700 
1 day 0.545 0.654 
3 days 0.583 0.513 
7 days 0.544 0.472 
14 days 0.482 0.0 
a antigen used in ELISA in determining anti-C aJbicans antibodies. 
b optical densities at 405 nm at a serum dilution of 1 :50. 
enolase antigenil 
infected 
mice 
0.540 
0.442 
0.058 
0.028 
0.0 
In subsequent challenge experiments mice treated with the IRS showed a 
significant delay in mortality (Fig. 2; P ~0.003). In contrast, mice treated with NRS or PBS 
all died within three weeks, most within two weeks (Fig. 2). No significant differences 
were found in survival between the PBS-treated and NRS-treated mice (P ~0.25). The 
three IRS-treated mice still alive at day 50 were sacrificed to obtain quantitative cultures 
of the organs. Lungs, liver and spleen were sterile whereas cultures of the kidneys 
revealed 1.7, 5.1 and 3.1 log CFU of C. albicans. Sera determined for two of the 
surviving mice, had high titers of autologous antibodies against the enolase and lower 
antibody titers against the crude antigen (Table 2). Please note that the sera of mice 
surviving at day 50 did not contain heterologous rabbit anti-Candida antibodies anymore. 
Protective role of IglRS fraction. To rule out that the observed protective effect 
of IRS was due to nonspecific serum factors the IRS was fractionated to obtain purified 
rabbit immunoglobulins. Again the IglRS showed a significant delay in mortality 
compared to the PBS (Fig. 2; P~0.003). The IglRS provided protection equal to that of 
complete IRS (P ~0.77). The three IglRS-treated mice, still alive at day 50 were sacrificed. 
Of one mouse all internal organs were steri Ie. From the other two mice Candida was 
cultured from the kidneys (respectively 3.5 and 4.8 log CFU of Candida/two kidneys). 
Again, sera determined for two of the surviving mice revealed high titers of autologous 
anti-enolase antibodies and less anti-crude antigen antibodies (Table 2). 
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Figure 2. Effect of repeated administration of IRS or IglRS on survival of immunocompetent mice 
with candidiasis. Mice were intraperitoneal treated with 0.4 mllRS (-0-) or IglRS (_e_) 4 h before 
i. v. inoculation with 3 x 10' CFU C. albicans and treated with 0.3 mllRS or IglRS at 6, 12 and 
18 days after Candida inoculation, Control mice were likewise treated with NRS (-y-) or PBS (-+-
). (number of mice treated was: IRS, n~21; IgIRS, n-17; NRS, n-22; PBS, n-27). *P ~ 0.003 
and *P<O.OOl versus NRS or PBS treated mice respectively, **P=O.003 versus PBS treated 
mice. 
Table 2. Antibodies against enolase and against crude antigen in IRS-, IgIRS-, and IMS-treated 
mice surviving C. albicans i. v. challenge for 50 days. 
mouse 
transferred anti-enolase anti-crude antigen 
with antibodiesa antibodiesa 
IRS 0.479" 0.118 
IRS 0.764 0.098 
IglRS 2.107 0.046 
IglRS 1.079 0.070 
IMS 1.217 0.281 
IMS 0.266 0.070 
a determined by using anti-mouse IgG conjugate. 
b optical densities at 405 nm at a serum dilution of 1 :400 
IRS, immune rabbit serumj IglRS, immunoglobulin fraction of immune rabbit serumi IMS, immune 
mouse serum. 
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Protective role of IMS. From the above described experiments it was not clear 
which antibody or antibodies were responsible for the protective effect observed. The 
IMS administered, targeted specifically toward the enolase antigen, induced a significant 
delay in mortality in comparison to NMS or PBS (Fig. 3; P~0.005 and P~0.015, 
respectively). NMS did not provide protection, the mortality rate was similar to the PBS-
treated controls. Two of the 15 IMS-treated mice, still alive at day 50 were sacrificed. C. 
albicans was only cultured from the kidneys (respectively 1.7 and 5.2 log CFU of c. 
albicans/two kidneys) the other internal organs were sterile. Both mice had higher titers 
of autologous anti-enolase antibodies than antibodies to the crude antigen extract (Table 
2). The specificity of the protective effect of the anti-enolase IMS was also confirmed by 
treating the mice with an anti-mannan monoclonal antibody which did not show any 
protective effect (fig. 3). 
To gain more insight into the potential mechanisms of the protective effect of the 
IMS, mice were sacrificed 1, 2, and 3 days after the onset of infection. Control mice 
treated with NMS and PBS were sacrificed at the same intervals. Quantitative cultures of 
their internal organs showed that administration of the IMS had no modulating effect on 
the number of C. albicans cells per organ during the initial 3 days after initiation of 
infection, as compared to the mice treated with NMS or PBS (Table 3). Similar results 
were found when the inoculum size was reduced to 4 x 10 4 CFU (data not shown). 
100 
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Figure 3. Effect of repeated administration of IMS or MAB 18C11 on survival of 
immunocompetent mice with candidiasis. Mice were intraperitoneal treated with 0.4 milMS (-0-) 
or MAB 18C1! (--.,-) 4 h before Lv. inoculation with 3 x 105 CFU C. albicans and treated witlJ 
0.3 mllMS or MAB 18C11 at 6, 12 and 18 days alter Candida inoculation. Control mice were 
likewise treated with NMS (-0-) and PBS (-+-). (number 01 mice treated was: IMS, n~ 15; MAB 
18C11, n~ 19; NMS, n ~ 10; PBS, n~ 27). 'P~ 0.005 versus NMS treated mice 'P~0.015 versus 
PBS treated mice. 
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Table 3. CFU of C. albicans per indicated organ at day I, 2, and 3 after inoculation with 3 x la' 
CFU C. albicans of mice given IMS, NMS or PBS 4 hr before. 
organ day 1 after LO,a day 2 after i.o. day 3 after i.o. 
IMS NMS PBS IMS NMS PBS IMS NMS PBS 
spleen 4.0b 3.9 4.3 3.6 3.8 4.0 4.16 3.8 3.8 
kidneys 5.0 4.9 5.1 5.4 5.9 6.5 6.9 6.4 6.6 
lung 3.0 2.8 3.0 2.9 2.7 3.3 3.6 2.9 3.1 
liver 4.6 4.5 4.7 4.2 4.3 4.5 4.7 4.4 4.3 
a La., inoculation. 
b log CFU of C. albicans (mean of 2 mice). 
In-vitro phagocytosis experiments. To study the influence of antisera against 
enolase on the phagocytosis and killing of C. albicans by macrophages, in vitro 
opsonization experiments were performed using peritoneal macrophage monolayers as 
indicator cells. Phagocytosis was determined after a 5 and 10 min incubation period since 
after 30 min Candida already started to form germtubes which influenced the 
reproducibility of the assay. From the data in Table 4 it can be seen that after 5 min of 
incubation differences in percentages of C. albicans phagocytosis were not significant 
between cells preopsonized with IRS, NRS and their respective immunoglobulin fractions 
or their heat-inactivated form. However, at 10 min of incubation macrophages had taken 
up significantly higher numbers of IRS- and NRS- preopsonized C. albicans cells 
compared to cells preopsonized with IgIRS, IgNRS, heat-inactivated IRS or NRS. Also, the 
percentage of macro phages participating_ in the phagocytic process was significantly 
higher (P<0.05; Kruskal-Wallis test) in these cases. Phagocytosis of IRS-opsonized 
Candida at 10 min of incubation did not significantly differ from that of the NRS-
opsonized yeast cells (Table 4). 
Similar results were observed for fresh IMS compared to heat-inactivated IMS and 
fresh NMS to inactivated NMS (Table 5). Already after 5 min of incubation phagocytosis 
of C. albicans opsonized with fresh anti-enolase serum was significantly higher than that 
of yeast opsonized with heat-inactivated anti-enolase serum. Phagocytosis of IMS-
opsonized Candida at 5 min of incubation did not significantly differ from that of NMS-
opsonized yeast cells (Table 5). A lower percentage of phagocytosing macrophages as 
well as a lower number of C. albicans cells per macrophage was observed if heat-
inactivated IMS were used to opsonize the Candida cells. Although the MAB 18Cll 
bound well to the cell wall of C. albicans, as determined by immunofluorescence, it did 
not promote phagocytosis. To the contrary, phagocytosis rates of 18Cl1 opsonized cells 
was similar to the PBS controls (Table 5). We were not able to detect killing of C. 
92 CI,apter 7 
albicans by the peritoneal macro phages regardless of the opsonins used to pretreat the 
yeast cells. 
Table 4. Effect of antiserum and purified antibodies against crude antigen on phagocytosis of C. 
albicans 
C. albicans cells ger macroghage % QhagoCJ:~tosing macroghages 
opsonin 5 min 10 min 5 min 10 min 
IRS 2.4 ±O.54 4.23 ±O.6a 59 ±6 86 ±4i 
NRS 2.7 ±o.s 4.17 ±0.9b 56 ±6 83 ±3b 
I Rslnaaivated 1.64 ±0.11 2.25 ±0.04 34 ±12 66 ±2 
NRslnadiYa!ed 2.09 ±0.11 2.27 ±0.04 52 ±s 59 ±1 
IglRS 2.19 ±O.44 3.19 ±o.s 48 ±7 66 ±6 
IgNRS 1.58 ±O.4B 2.55 ±0.23 51 ±s 70 ±6 
, IRS significantly different from IRS'''"·'''' and IglRS (P < 0.05; Kruskal-Wallis test) 
b NRS significantly different from NRS""""""' and IgNRS (P < 0.05; Kruskal-Wallis test) 
IRS, IgIRS; anti-crude antigen antibody rabbit sera or immunoglobulin fraction 
NRS, IgNRS; normal rabbit serum or immunoglobulin fraction. 
Table 5. Effect of anti-enolase antibodies antigen antisera on phagocytosis of C. albicans 
C.albicans cells ger macroghage % ghagocrlosing macroghages 
opsonin 5 min 10 min 5 min 10 min 
IMS 2.65 ±O.7d 3.33±o.78a 59 ±6a 70 ±6c 
NMS 2.3 ±O.llb 2.84±o.51b 53 ±7b 44 ±12 
IMslnactivatro 1.67 ±O.O2 1.88 ±0.17 22 ±3 47 ±7 
NMS1Nctiva!ro 1.29 ±0.12 1.73 ±0.03 5 ±1 30 ±s 
18Cll 1.83 ±0.46 2.69 ±O.7B 16 ±3 39 ±1O 
PBS 2.14 ±O.26 2.39 ±0.17 10 ±s 32 ±7 
a IMS significantly different from IMSlnactiv~!ro, NMSlnadivatro, l8Cll, and PBS (P<O.OSi Kruskal~ 
Wallis test). 
b NMS significantly different from NMsinactivatro (P<0.05i Kruskal~Waliis test) 
'IMS significantly different from all other opsonins (P<O.Ol; Kruskall-Wallis lest) 
IMS, anti~enolase antigen mouse serumi NMS, normal mouse serumi l8Cll, monoclonal anti-
mannan antibody. 
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DISCUSSION. 
Several studies have described delayed mortality after the administration of specific 
antibodies in animal models of deep-seated candidiasis (12, 13, 17, 19). Antibodies used 
were mostly polyclonal and raised against a variety of undefined Candida antigens. 
Matthews et al. (13), however, demonstrated protection which was achieved by the 
administration of antibodies specifically directed toward a 47 kDa immunodominant 
antigen. 
In the present study we evaluated the effect on mortality in a model of chronic, 
but ultimately fatal candidiasis, of antibodies raised against a variety of undefined 
antigens (IRS) and against the specific enolase antigen (lMS). The reason for studying anti-
enolase antibodies for its protective capacities is the fact that enolase has been shown to 
be an immunodominant antigen in patients with invasive candidiasis (25). In this respect 
enolase is comparable to the immunodominant 47 kDa break down product of the 90 
kDa heat shock protein (13). As Mourad et aI., (17) reported that the mortality rate 
became similar to that of controls if the administration of antibodies is prematurely 
stopped, the design of a study aimed at demonstrating protection should assure a 
sufficient and constant antibody level in the blood of the experimental animal. Fulfilment 
of these conditions was achieved in our study by repeated injections of the antisera with 
an interval of 6 days. Experiments in which antiserum was administered only once 4 
hours before initiation of infection failed to show any protective effect (data not shown). 
These findings might also explain the results of Kagaya et aI., (10) who reported lack of 
effectiveness of specific immunoglobulins administered only once every two weeks. 
A protective effect in our model could only be shown in mice which had received 
three repeated doses of IRS, IglRS or IMS. All three regimens had similar protective 
effects. The experiment in which mice were treated with IglRS indicate that the protective 
effect is largely mediated by the antibodies present in the immune sera and not due to 
non-specific heat-labile serum factors. The IMS we used is a well defined polyclonal 
antiserum, monospecific for enolase. In contrast, IRS was directed toward various 
undefined antigenic determinants present in the crude Candida extract. The results 
obtained with the IMS correlate well with the findings of Matthews et aI., (13) who also 
demonstrated a protective effect with an antiserum directed specifically against another 
(the 47 kDa) immunodominant antigen. The specificity of the protective effect of anti-
enolase antibodies was underlined by the results of MAB 18Cll. 
Another finding which underlines the potential protective effect of anti-enolase 
antibodies is the fact that mice surviving for 50 days after the Candida challenge have 
high levels of circulating anti-enolase antibodies; this would indicate that these mice 
have, by that time, developed antibodies against the enolase that may have helped to 
extend their survival. These antibodies had to be of mouse origin as indirectly proven in 
animals given IRS or IglRS who had high proportions of autologous mouse anti-enolase 
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antibodies. 
To gain insight into the mechanism(s) of decreased mortality observed with 
immune-sera, the lungs, liver, spleen, and kidneys were cultured of mice sacrificed during 
the first three days. No significant effect on the number of C. albicans cultured in these 
organs was observed after IMS treatment. From this it was concluded that the protective 
effect is not the result of an early decrease in the number of viable CFU's per organ. 
Presumably effects of immune sera occur later in the infection process, as suggested by 
others (16, 22). 
The effect of immune sera (lMS and IRS) could not simply be explained by 
enhancement of the phagocytic process by leukocytes or macrophages through an 
opsonic mechanism. In in vitro experiments increased uptake was seen with the IMS- or 
IRS·opsonized C. albicans cells; however, in the control experiments using non-immune 
sera similar increases in Candida uptake were observed. From these opsonophagocytosis 
experiments it became clear that the opsonic effect of immune serum is to a significant 
degree dependent upon complement-activation since heat-treated sera were much less 
opsonic. Although complement promoted the rate of phagocytosis it did not enhance the 
intracellular killing of C. albicans by peritoneal macrophages as was postulated by Pereira 
and Hosking (20). Surprisingly, monoclonal anti-mannan antibodies did not enhance 
phagocytosis although the antibody clearly bound to the surface of the Candida cells. 
Lack of opsonic activity of this IgG class antibody is not expected and in any case points 
to an inability to interact with FC-receptors on the macrophage. 
Another somewhat puzzling finding is the fact that most of the internal organs of 
the mice surviving at day 50 were sterile except for the kidneys. This failure to clear 
Candida from the kidneys might imply that the anti-Candida activity of antibodies is 
anatomically restricted. Sohnle et aI., (23) reported that the infiltration of monocytes into 
infectious loci is enhanced in the presence of antibodies. However, histopathological 
examinations! even in immunized micel showed infiltration of granulocytes 
predominantly and less mononuclear cells in the kidney, which slowly changes at varying 
times after challenge with C. albicans (22). This slow infiltration of mononuclear cells 
may help explain the unique susceptibility of the kidney to Candida infections (22), 
which would restrict antibody-mediated protection through mononuclear cells to only the 
later stages of Candida infection. Immunotherapy with specific antibody, therefore, seems 
to protect predominantly the organs of the reticuloendothelial system whereas other 
interactions are needed to enhance resistance against renal candidiasis (22). 
There are still a number of remaining questions as to the mechanism involved of 
these antibody protective effects. Probably, antibody dependent antigen presentation to 
T-cell may have been involved, allowing earlier recognition of C. albicans cells, probably 
combined with enhancement of cell mediated mechanisms, which might have resulted 
in increased survival. Therefore, we conclude, as have others, that protective immunity 
against systemic candidiasis involves a combination of innate defenses, humoral and 
Protective anti-enolase antibodies 95 
cellular immunity (11). 
In conclusion, we have shown that enolase-specific antibodies provide partial 
protection against lethal C. albicans infections, an observation that warrants their further 
evaluation in future studies. 
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GENERAL DISCUSSION 
C. albicans is an opportunistic pathogen of the human gastrointestinal tract that 
takes advantages of factors which decrease the normal host resistance and increase the 
concentration of yeast in the gut such that it can invade across the mucosa of the 
gastrointestinal tract and disseminate (1, 2, 3). Haematogenous dissemination of c. 
albicans can lead to infection in virtually every organ or tissue of the human body. These 
infections are among the most important causes of morbidity and mortality among 
patients with cancer and those that are otherwise severely immunocompromised (1). 
Despite awareness of the seriousness of the Candida infections, diagnosis of invasive 
candidiasis remains difficult (4). 
The aim of this study was to develop diagnostic techniques which are easy to 
apply and have a high sensitivity and specificity for diagnosing invasive candidiasis. 
Diagnostic tests can be divided into culture dependent and non·culture dependent 
techniques. By microbiological techniques the yeast is demonstrated in patient specimens 
by culture or microscopy. Non·culture techniques include the detection of anti-Candida 
antibodies, antigens, metabolic products of Candida, and more recently the 
demonstration of species-specific DNA or RNA sequences, in blood or other body fluids. 
Anti·Candida antibodies were studied extensively in the 1960s and 1970s (5-9). 
The major drawback of these early studies is that crude undefined non·standardized 
antigen preparations were used for antibody detection (10, 11). Also, for evaluation of 
the assays often not properly characterized patient populations were used; 
immunodeficient patients and immunocompetent patients were combined within one 
group or patients with oesophagi tis were classified as having invasive candidiasis (12). 
The specificity of the assays was often related to undefined control groups (13, 14). We 
describe the diagnostic use of serological assays by making use of well·characterized 
antigens for antibody detection. Assays were evaluated in sera of immunodeficient and 
immunocompetent patients with invasive candidiasis and in sera of matched control 
groups of C. albicans colonized patients. We showed that the diagnostic accuracy of 
antibody detection by a counter immunoelectrophoresis technique in a group of surgical 
patients could be improved by using cytoplasmic antigens depleted of mann an and 
glycoproteins. The specificity of the counter immunoelectrophoresis assay increased from 
28.6% to 78.6% if the cytoplasmic antigen was depleted of mann an; the sensitivity 
sl ightly decreased from 80 to 70%. 
Since cytoplasmic antigens are released during invasive infection, it is conceivable 
that such antigens when applied in an antibody detection assay, could discriminate 
between invasive infection and colonization (10). Matthews et al. (15) and Porsius et al. 
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(16) analyzed the antibody response by Western blotting and demonstrated that 
antibodies directed against an immunodominant antigen of C. albicans with a molecular 
mass of 47 kDa correlated with invasive infection. However, several immunodominant 
antigens with different molecular weight have been identified (17, 18, 19, 20, 21). 
Probably all these immunodominant cytoplasmic antigens are either identical or closely 
related. 
The immunodominant antigen was characterized by Western blot analysis and 
tandem crossed immunoelectrophoresis as the glycolytic enolase enzyme with a 
molecular weight of 45 kDa. By using the enzyme-linked immunosorbent assay (ELISA), 
the diagnostic sensitivity and specificity of antibodies directed against this purified 
enolase antigen was evaluated. The anti-enolase antibody response was measured in sera 
of immunocompetent and immunocompromised patients with either invasive candidiasis 
or C. albicans colonization. The diagnostic specificity of the enolase ELISA was high up 
to 86% for the immunocompetent patient group. However, even if multiple serum 
samples were used the gain in specificity was counteracted by a loss of sensitivity, i.e. 
a decrease from 80 to 50% compared with that of the counter immunoelectrophoresis 
with crude cytoplasmic antigen. This loss in sensitivity probably cannot be amended by 
using more sensitive detection assays, but rather calls for a combination of tests with 
other antibody, antigen, or metabolite detection assays. We further showed that by using 
healthy donors as a control group the specificity reached 100%, indicating the 
importance of a matched control group in determining the specificity of a diagnostic 
assay. For the immunodeficient patient group the anti-enolase ELISA showed significantly 
higher titers in the sera of patients with invasive candidiasis than in the sera of patients 
only colonized by C. albicans, however these patients generally showed lower anti-
enolase antibody titers than those found in the sera of immunocompetent patients. In 
extremes, patients with leukemia and invasive candidiasis did not have detectable anti-
enolase antibodies at all. 
In the immunodeficient patient group the use of a crude antigen for antibody 
detection had a higher sensitivity than the same antigen depleted of mannan. Therefore, 
an assay with an acceptable sensitivity might be obtained in the immunocompromised 
patient by detecting anti-mannan antibodies. Since anti-mannan antibodies are universally 
present in sera of patients with either invasive candidiasis, Candida colonization or 
healthy individuals (22), our test assay was standardized and a cut off value was applied 
in order to obtain an acceptable specificity. Furthermore, to gain insight into the antibody 
kinetics of anti-mann an and anti-cytoplasmic antibodies, patients were followed 
serologically in time. Serial evaluation of test results is important because serological test 
results of a single serum sample are heavily biased by the moment of blood sampling in 
relation to the usually unknown stage of the Candida infection. Thus, improper sampling 
\ 
may give rise to false negative results. The increase in anti-mannan antibody levels was 
demonstrated to be an early indicator for invasive candidiasis. This rapid rise in anti-
mannan antibodies is probably due to a secondary immuneresponse. We therefore, 
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recommend to search for increases in anti-mann an antibody titers in several sera of 
immunocompromised patients during the progression of infection since this avoids the 
limitations of interpreting the test results of a single serum sample (23, 24, 25). The 
clinical usefulness of follow-up of anti-mann an antibody titers for detection of Candida 
infections was recently confirmed in a study of children with malignant disease and 
invasive candidiasis (26). However, anti-mann an antibodies in this particular study were 
not early indicators for invasive candidiasis since the children's antibody response is a 
primary and not a secondary immuneresponse as is the case with adult patients. Similarly 
determining increases in anti~enolase antibodies in several sera of immunocompetent 
patients will be very useful in confirming a diagnosis of invasive infection in such 
categories of patients. 
Interestingly, antigen titers in sera of immunocompromised patients, although 
discriminating between invasive candidiasis and C. albicans colonization, did not 
correlate with the pathogenesis of the Candida infection process. We demonstrated that 
antigen detection in immunocompromised patients is usually not the test of choice. 
Probably, the processing of yeast cells by phagocytic cells is necessary for the release of 
sufficient amounts of antigens into the circulation (27). In an attempt to improve the 
predictive value of the assay with respect to invasive candidiasis the results of the 
antibody assays were combined with the antigen titers obtained by the Cand-Tec assay. 
However, no significant increase in predictive power was obtained by this combination 
as determined by multivariable analysis. Research for the detection of new antigens from 
yeast cells or hyphae of Candida spp. related to invasive candidiasis is ongoing. In this 
respect, Candida metabolites are believed to be very important clues that can be used for 
diagnosis. Especially, the detection of D-arabinitol and 1,3-g-D-glucan (28, 29, 30, 31, 
32). Unfortunately, there is yet no commercial test for these metabolites available that can 
be used in clinical laboratories. 
Efforts to further improve the diagnosis of invasive candidiasis by serological assays 
are still going on, but it is highly questionable whether the sensitivity and specificity of 
one single test can be optimalized to become clinically relevant. The combined use of 
the anti-mann an and anti-enolase antibody detection assays in relation to the underlying 
disease of the patient would probably improve the accuracy of a diagnosis of invasive 
infection. Further improvements are possibly accomplished by detecting specific IgG, IgM 
andlor IgA antibodies directed towards these mannan and enolase antigens. 
Since the sensitivity of a serological assay is influenced by the immunestatus of the 
patient and the moment of sampling during the infection process, we evaluated the peR 
as a diagnostic tool in the detection of invasive candidiasis. Our peR makes use of 
primers aimed at the multicopy gene coding for the small subunit rRNA resulting in the 
synthesis of a 180 bp fragment. With the use of a C. albicans specific probe, 10 to 15 C. 
albicans cells could be detected in 100 pi of whole blood by Southern analysis. peR 
analysis of blood specimens collected from mice with invasive candidiasis was more 
sensitive than blood cultures (100% versus 67%, respectively). Furthermore, the intensity 
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of the hybridization signals increased with the progression of infection. Negative results 
by peR were found for mice gastrointestinally colonized only. This observation 
underlines the specificity of this peR method. However, the lower limit of Candida cells 
that could be detected in blood samples could not further be improved by using more 
target DNA or other sample preparations. Improvements in peR methodology, by using 
other strategies for Candida cell isolation from clinical specimens or by using rRNA may 
in the future lead to acceptable levels of sensitivity. The amplification of rRNA by nucleic 
acid sequence-based amplification is also faster than PCR (33), and its amplification 
enzymes potentially are less sensitive to inhibitory factors in blood which makes it an 
interesting technique to be compared to PCR. 
Apart from helping to diagnose invasive candidiasis, an ideal assay should also 
help in monitoring the response to treatment and, thus, in determining the duration of 
therapy. We used PCR in monitoring the therapeutic efficacy to antifungal treatment. This 
prognostic aspect of the PCR assay was evaluated in a model of lethal C. albicans 
infection in neutropenic mice, who were treated with the antifungal agent AmBisome® 
at doses of 1, 7 and 14 mg AmB/kg body weight, respectively. Blood cultures of infected 
mice treated with three different doses of AmBisome® were only positive at the early 
onset of the infection process and became sterile after three days even in those mice that 
had a relapse of infection 14 days later. However, this relapse of infection as expressed 
in the number of CFU in the kidney, correlated well with the hybridization signals of the 
PCR. PCR data correlated well with the therapeutic response to antifungal treatment. 
However, to establish its clinical value this PCR warrants further evaluation in patients 
at risk for candidiasis. Further improvements in PCR technology involve, among others, 
reducing the number of steps in the DNA extraction procedure. 
Besides improving the diagnosis of invasive candidiasis by developing sensitive 
and specific assays, we also studied the mechanism of host defense against C. albicans 
infections. The mechanism of host defense against C. albicans infections has been the 
subject of great interest and controversy for many years (34, 35, 36, 37, 38, 39). 
Generally, the humoral response is thought to be less important in host resistance to 
Candida spp. than cellular immune factors; however, several studies have suggested that 
anti-Candida antibodies may protect against invasive candidiasis. We evaluated the 
protective capacities of antibodies directed against the immunodominant enolase antigen 
of C. albicans, and compared its activity to that of antibodies directed against a crude C. 
albicans antigen extract and that of a monoclonal antibody directed against mannan. 
Passive transfer of anti-enolase antibodies and of antibodies directed against a crude C. 
albicans extract provided significant protection against lethal C. albicans infections in 
mice. In contrast, no protection was obtained with the monoclonal antibody against 
mannan. The immunoprotection was not due to better initial clearance of c. albicans 
from the internal organs but was presumably the result of an as yet unknown effect of 
antibodies occurring later in the infection process. The in vivo results could also not be 
ascribed to enhanced opsonization of the yeast cells as observed in in vitro opsonization 
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experiments. The protective effect observed with anti-enolase antibodies can be due to 
enhanced T- and B-Iymphocyte functions, the stimulation of cytotoxic activity of 
peripheral blood mononuclear cells and natural killer cells or they could assists in the 
chemotaxis of leucocytes to the site of infection and enhance phagocytosis of Candida 
cells. Undoubtly none of these reactions occur independently but indicate that humoral 
factors and cellular factors may cooperate in the defense against invasive candidiasis. One 
may speculate that the clinical application of enolase-specific antibodies may retard or 
delay the infectious process, and increase the effectiveness of antifungal therapy. 
However, this hypothesis warrants further evaluation in future studies. 
REFERENCES 
1. Odds, F. Candida and candidosis: a review and bibliography book. 
2. Samonis, C., A. Gikas, P. Tolondis, S. Marakit G. Vrentos, Y. Tselentis, N. Tsaparas, and G, 
Bodey. 1994 Prospective study of the impact of broadspectrum antibiotics on the yeast flora of the 
human gut. Eur. J. Clin. Microbial. Infect. Dis. 13:665-667. 
3, lopez-Ribot, J. L., C. S. McVay, and W. l. Chaffin. 1994. Murine tissue exposed to cytotoxic 
drugs altered patterns of Candida albicans adhesion. Infect. Immun. 62:4226-4232. 
4. pfaller, M. A. 1992. Laboratory aids in the diagnosis of invasive candidiasis. Mycopathologica 
120:65·72. 
5, Guinan, M. E., M. R. Porras, and H. R. Hill. 1979. The Candida precipitin test in an 
immunosuppressed population. Cancer 43:299-302. 
6. Harding, S. A., G. R. Sanford, and W. G. Merz. 1976. Three serologic tests for candidiasis: 
diagnostic value in distinguishing deep or disseminated infection from superficial infection or 
colonization. Am. J. Clin. Pathol. 65:1001-1009. 
7. Kozinn P. j., C. l. Taschdjian, and P. K. Goldberg et al. 1978. Efficacy of serologic tests in the 
diagnosis of systemic candidiasis. Am. J. Clin. Pathol. 70:893-898. 
8. Kozinn P. ,., C. l. Taschdjian, P. K. Goldberg, G. J. Wise, E. F. Toni, and M. S. Seelig. 1978. 
Advances in the diagnosis of renal candidiasis. J. Uro!' 119:184-187. 
9. Taschdjian, C. L, P. J. Kozinn, M. V. Cuesta, and E. F. Toni. 1971. Serodiagnosis of candidal 
infections. Am. J. Clin. Patho!. 57:195-205. 
10. de Repentigny, L, and E. Reiss. 1984. Current trends in immunodiagnosis of candidiasis and 
aspergillosis. Rev. Infect. Dis. 6:301-312. 
11. Jones, M. J. 1990. laboratory diagnosis of invasive candidiasis. Clin. Microbiol. Rev. 3:32-45. 
12. Fisher, J. F., R. C. Trincher, J. F. Agel, T. B. Buxton, C. A. Walker, D. H. Johnson, R. E. Cormier, 
W. H. Chew, and J. P. Rissing. 1985. Disseminated candidiasis: A comparison of two immunologic 
techniques in the diagnosis. Am. J. Med. Sciences 290:135-142. 
13. Kohno, S., K. Mitsutake, S. Maesaki, A. Yasuoka, T. Miyazaki, M. Kaku, H. Koga, and K. Hara. 
1993. An evaluation of serodiagnostic tests in patients with candidemia: beta·glucan, mannan, 
Candida antigen by Cand-Tec and d-arabinitol. MicrobiollmmunoI.37:207-212. 
14. Merz, W. G., l. Evans, S. Shadomy, S. Anderson, L Kaufman, P. J. Kozinn, D. W. Mackenzie, W. 
P. Protzman, and J. S. Remington. 1977. laboratory evaluation of serological tests for systemic 
candidiasis: a cooperative study. J. Clin. Microbiol. 5:596-603. 
15. Matthews, R. c., J. P. Burnie, and S. Tabaqchali. 1984. Immunoblot analysis of the serological 
response in systemic candidiasis. The lancet 22/24:1415-1418. 
16. Porsius, J. c., H. J. A. van Vliet, J. H. van Zeijl, W. H. F. Goessens, and M. F. Michel. 1991. 
Detection of antibody response in immunocompetent patients with systemic candidiasis, or 
Candida a/bicans colonization. Eur. J. Clin. Microbial. Infect. Dis. 9:352·355. 
17. Franklyn, K. M., J. R. Warmington, A. K. OU, and R. B. Ashman. 1990. An immunodominant 
antigen of Candida a/bicans shows homology to the enzyme enolase.lmmuno!. Cell. BioI. 68:173· 
102 Chapter 8 
178. 
18. Karwowska, A., and B. liso\Vska·Grospierre. 1984. Diagnostic significance of the human antibody 
response to a major cytoplasmic antigen of C. albicans. Immunology letters 8:127-129. 
19. Bodey, G. P., and E. J. Anaissie. 1989. Chronic systemic candidiasis. Eur. J. Clin. Micrbiol. Infect. 
Dis. 8:855·857. 
20. Jones, J. M. 1980. Quantitation of antibodies against cell wall mannan and a major cytoplasmic 
antigen of Candida in rabbits, mice, and humans. Infect. Immun. 30:78-89. 
21. Greenfield, R. A'I L. T. Troutt, R. C. Richard, and D. H. AUmiller. 198a. Comparison of antibody, 
antigen, and metabolite assays in rat models of systemic and gastrointestinal candidiasis. 1. Clin. 
Microbial. 26:409-417. 
22. Faux, J. A'I A. E. Agbarakwe, S. A. Misbah, and H. M. Chapel. 1992. A comparison of specific IgG 
antibody levels to the cell wall mannan of Candida a/bicans in normal individuals and in patients 
with primary antibody deficiency. J. Immunol. Methods 153:167·172. 
23. Jones, J. M. 1980. Kinetics of antibody responses 10 cell wall mannan and a major cytoplasmic 
antigen of Candida afbicans in rabbits and humans. J. lab. Clin. Med. 96:845-860. 
24. Kostiala, I., A. A. I. Kostiala, U. larinkari, V. V. Valtonen, and A. Miettinen. 1981. Antibodies 
against antigen of Candida afbicans in patients with fungemia and bacteraemia, studied by ELISA, 
precipitation, passive haemagglutination, and immunofluorescense.J. Med. Microbial. 14:483-492. 
25. Mauch, H. 1983. Diagnostic value of monitoring kinetics of antibody response in candidiasis by 
a solid-phase radioimmunoassay. Am. J. Clin. Pathol. 79:200-205. 
26. Ormala, T., M. Korpi, M. L. Katila, T. Ojanen, and M. Perkkio. 1995. Prospective evaluation of 
Candida antigen and antibody assays {ordelection of Candida infections in children with malignant 
disease. Acta. Paediatr. 84:183-187. 
27. Mohart, M., R. Ronnie, B. Ziola, E. Bow, and T. J. Louie. 1994. Evaluation of enzyme 
immunoassay for Candida cytoplasmic antigens in neutropenic cancer patients. J. Clin. Microbial. 
32:766-776. 
28. Gold, J. W. M., B. Wong, Eo M. Bernard, T. E. Kiehn, and D. Armstrong. 1983. Serum arabinitol 
concentrations and arabinitol!creatinine ratios in invasive candidiasis. J. Infect. Dis. 147:504-513. 
29. Roboz, J., R. Suzuki, and J. F. Holland. 1980. Quantification of arabinitol in serum by selected ion 
monitoring as a diagnostic technique in invasive candidiasis. J. Clin. Microbiol. 12:594-602. 
30. Walsh, T. J., J. W. lee, T. Sien, R. Schaufele, J. Bacher, A. C. Switchenko, T. C. Goodman, and 
P. A. Pizzo. 1994. Serum D-arabinitol measured by automated quantitative enzymatic assay for 
detection and therapeutic monitoring of experimental disseminated candidiasis: correlation with 
tissue concentrations of Candida albicans. J. Med. Vet. Mycol. 32:205-215. 
31. Ikegani, K., K. Ikemura, and T. Skimazu. 1988. Early diagnosis of invasive candidiasis and rapid 
evaluation of antifungal therapy by combined use of conventional chromogenic Limulu5 test and 
newly developed endotoxin specific assay. J. Trauma 28:1118-1126. 
32. Morita, T., S. Tanaka, T. Nakamura, and S. Iwanaga. 1981. A new l,3-B-D-glucan-mediated 
coagulation pathway found in Limulu5 ameboyle. FEBS lett. 129:318-321. 
33. van der Vliet, G. M. E., R. A. F. Schukkink, B. van Gemen, P. Schepers, and P. R. Klatser. 1993. 
Nucleic acid sequence-based amplification (NASBA) for the identification of mycobacteria. J. Gen. 
Microbial. 139:2423-2429. 
34. Maiti, P. K., A. Kumar, R. Kumar, and l. N. Mohapatra. 1985. Role of antibodies and effect of 
BCG vaccination in experimental candidiasis in mice. Mycopathologica 91:79-85. 
35. Hasenclever, H. F., and W. O. Mitchell. 1962. Acquired immunity to candidiasis in mice. J. 
Bacterial. 86:401-406. 
36. Cantora, M. T., and E. Bafish. 1992. Reply [letter]. 1. Infect. Dis. 166:194-195. 
37. Mourad, S., and l. Friedman. 1986. Passive immunization of mice against Candida albicans. 
Sabouraudia.6:103-105. 
38. Matthews, R. c., J. P. Burnie, D. Howat, T. Rowland, and F. Walton. 1991. Autoantibody to heat· 
shock protein 90 can mediate protection against systemic candidosis. Immunology 74:20-24. 
39. Pearsall, N. N., and D. lagunoff. 1974. Immunological responses to Candida afbicans. I. Mouse-
tigh lesion as model for experimental candidiasis. Infect. Immun. 9:999-1002. 
103 
SUMMARY 
During the past decades the frequency of invasive Candida infections has 
increased significantly. This is primarily due to a growing group of immunocompromised 
patients, who due to new kinds of medical treatment are kept alive for prolonged periods 
of time. However, these patients carry several risk factors for obtaining invasive 
candidiasis. These risk factors include the use of cytostatic and immunosuppressive 
agents, the use of broad-spectrum antibiotics, and long periods of central vein catheters, 
or the presence of other accessories to the tissue. 
The greater part of the invasive infections is still caused by Candida albicans. 
However, other Candida species are isolated with increased frequency from infected 
patients. These yeasts are opportunistic pathogens and belong to the normal human 
gastrointestinal system and live under normal circumstances in balance with the cells of 
the skin or mucous membranes of the host. Disturbance of this balance due to the 
previous mentioned risk factors, can lead to overgrow of these yeasts resulting in 
superficial infections of the mucous membranes or invasive infections of Virtually every 
organ of the body. 
Superficial infections are relatively easy to recognize and can usually be treated 
with topical agents. In contrast, invasive infections have no specific clinical picture and 
require systemic treatment. Because systemic antifungal agents are toxic it is important 
to distinguish superficial infections from invasive infections. 
The diagnosis of invasive candidiasis is difficult: biopsies cannot be performed 
routinely, and blood cultures often remain negative. On the other hand isolation of C. 
albicans from sputum, urine, or feces is no proof of invasive candidiasis. A correct 
diagnosis is very important since mortality is high in patients with invasive candidiasis 
who are not promptly treated systemically with toxic antifungal agents. Therefore, 
serodiagnostic results are of growing importance in diagnosing invasive candidiasis. 
Serodiagnosis is currently not fully reliable due to the commensal character of the yeasts, 
which can cause false-positive results, or can lead to false-negative results due to a lack 
of an immuneresponse in immunocompromised patients. 
It is furthermore known that antibodies directed against the cell wall mannan, are 
universally present in patients with invasive candidiasis, in patients with superficial 
infections, and in healthy individuals. Therefore, antigens related to the invasive form of 
infection have been used for the detection of antibodies directed against Candida species. 
In this thesis the usefulness of antibodies directed against cytoplasmic antigens in 
the diagnosis of invasive candidiasis in immunocompetent patients was investigated 
(Chapter 2). The antibody response directed against mannan-free cytoplasmic antigens 
[MOl was compared with the antibody response directed against a crude C. albicans 
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extract including cell wall mannan [M( +)], by using the counterimmunoelectrophoresis 
technique (CIE). Both antibody responses were evaluated in sera of surgical patients with 
either invasive or superficial candidiasis. These results showed an increased diagnostic 
specificity by using M(-) CIE (78.6%) compared to M( +) CIE (28.6%), with a minimum 
loss in diagnostic sensitivity from 80 to 70% which makes it a more reliable diagnostic 
assay for this particular patient group. It was further shown that during the first two weeks 
after the clinical signs of invasive candidiasis the amount of positive antibody titers 
increased from 50 to 67%. This work provided further evidence that the use of 
cytoplasmic antigens of C. albicans for the detection of antibodies improved the 
serodiagnosis of invasive candidiasis for the immunocompetent patients. 
To further improve serodiagnosis of invasive candidiasis we purified an 
immunodominant antigen, a glycolytic enolase enzyme, in order to detect specific 
antibodies. The anti-enolase antibody response was evaluated in sera of 
immunocompetent and immunocompromised patients with either invasive candidiasis or 
C. albicans colonization (Chapter 3). The enzyme-linked immunosorbent assay (ELISA) 
was used in order to develop a quantitative and sensitive antibody detection assay. The 
diagnostic specificity of the enolase ELISA was high up to 86% for the immunocompetent 
patient group. Despite the use of multiple serum samples, the increase in specificity was 
counteracted by a loss of sensitivity, i.e. a decrease from 80 to 50% compared with that 
of the M( + )CI E. However, the good specificity of the enolase ELISA may well support the 
clinician in making a decision allowing to or withhold toxic antifungal agents. For the 
immunodeficient patient group, the enolase EliSA showed significantly higher titers in 
the sera of patients with invasive candidiasis than in the sera of patients only colonized 
by C. albicans. However, these patients generally showed lower anti-enolase antibody 
titers compared to immunocompetent patients. Patients with leukemia and invasive 
candidiasis did not have detectable anti-enolase antibodies at all (Chapter 3). The 
detection of anti-mannan antibodies would probably be more accurate for serodiagnosis 
of invasive candidiasis in immunodeficient patients. 
Serial determination of antibody responses against cytoplasmic antigens and a 
crude Candida extract as well as antigen detection was evaluated in 
immunocompromised patients (Chapter 4). The increase in anti-mannan antibody levels 
was demonstrated to be an early indicator for invasive candidiasis in these patients. This 
study illustrated that the anti-mannan antibody determination is of value in 
immunocompromised patients to confirm the diagnosis of Candida infection and that it 
can be used to follow the progression or resolution of systemic candidiasis. Measuring 
the kinetics of the antibody titers during the pathogenesis of a systemic Candida infection 
also overcomes the limitation of interpreting the test results of a single serum sample. 
Titers of antigen, although discriminating between invasive candidiasis and C. albicans 
colonization, did not correlate well with the infectious process of candidiasis. Therefore, 
antigen detection does not seem to be the test of choice in immunocompromised 
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patients. It was considered that different serological criteria are necessary for the diagnosis 
of invasive candidiasis in patients with different kinds of underlying diseases, e.g. 
leukemic patients and patients undergoing surgery. 
The diagnosis of invasive candidiasis could possibly be improved by the use of 
molecular techniques. Small quantities of cells can then be detected in patient specimens. 
These methods are also faster than the long incubation periods needed in classical culture 
techniques. The polymerase chain reaction (PCR) was used for the amplification of a 
small subunit ribosomal RNA gene that is conserved among many fungi. With the use of 
a C. albicans.specific probe, 10 to 15 C. albicans cells were detected in 100 pi of whole 
blood by Southern analysis (Chapter 5). The diagnostic value of this PCR was evaluated 
in gastrointestinally colonized mice and neutropenic mice with invasive candidiasis. 
Negative results by the PCR were found for gastrointestinally colonized mice which 
underlines the specificity of this PCR method. PCR analysis of blood specimens collected 
from mice with invasive candidiasis were more often positive than blood culture, 100% 
compared to 67% determined at 72 hours after the onset of infection (Chapter 5). 
Furthermore, the intensity of the hybridization signals increased with the progression of 
infection. This is what might make the PCR assay useful in the follow-up of invasive 
candidiasis during treatment. 
This prognostic aspect of the PCR assay was evaluated in a model of a lethal C. 
albicans infection in neutropenic mice, who were treated with different doses of 
liposomal Amphotericin B (AmBisome) (1, 7, and 14 mg of AmB per kg of bodyweight) 
in order to establish different courses of the infectious process (Chapter 6). Mice treated 
with 4 daily doses of 7 or 14 mg of AmB per kg were culture sterile at 35 days after 
inoculation with 10' CFU C. albicans, whereas the lungs, livers, and spleens of mice 
treated for 4 days with 1 mg of AmB per kg experienced a relapse of infection 21 days 
after inoculation with 10' CFU C. albicans. This relapse of infection correlated with an 
increased intensity of the hybridization signals of the PCR, whereas blood cultures of the 
same blood samples remained culture sterile. Again the PCR proved to be more sensitive 
than blood culture and correlated with the course of infection during antifungal therapy. 
Besides the diagnostic use of antibodies directed against several antigens of C. 
albicans, their role in the mechanism of host defense against invasive candidiasis has 
been the subject of great interest and controversy for many years. In Chapter 7 we 
evaluated the protective capacities of antibodies directed against the immunodominant 
enolase antigen of C. albicans, and compared its activity to that of antibodies directed 
against a crude C. albicans antigen extract and a monoclonal antibody directed against 
mannan (MAB 18C11). Passive transfer of anti·enolase antibodies, raised in mice (lMS) 
and antibodies directed against a crude C. albicans extract, raised in rabbits (IRS) when 
repeatedly administered, provided partial protection against lethal C. albicans infections 
in mice, whereas no protection was obtained with the MAB 18C11. The 
immunoprotection was not due to an initial clearance of C. albicans from the internal 
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organs but was presumably the result of as yet unknown effects of antibodies occurring 
later in the infection process. The in vivo results could not be ascribed to enhanced 
opsonization of the yeast cells as observed in in vitro opsonization experiments using 
peritoneal macrophage monolayers. The use however of this observed protection of 
enolase-specific antibodies against lethal C. afbicans infection may first permit a delay of 
the infectious process which may be very important in the effective treatment with 
antifungal agents, but warrants further evaluation in future studies. 
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De laatste decennia is het aantal invasieve Candida infecties toegenomen. Dit 
heeft met name te maken met een groeiende groep van immuun gecompromiteerde 
patienten die dankzij nieuwe behandelingsmethoden lange tijd in leven kunnen worden 
gehouden. Deze patienten dragen echter een of meerdere risicofactoren voor het krijgen 
van een invasieve Candida infectie met zich mee. Onder deze risicofactoren verstaan we 
het gebruik van cytostatica en immuunsuppresiva, het gebruik van breedspectrum 
antibiotica en het langdurig in situ verblijf van intraveneuze catheters. 
Het merendeel van de invasieve infecties wordt nag altijd veroorzaakt door 
Candida albicans. Er worden echter steeds vaker andere Candida soorten bij 
gernfecteerde patienten gersoleerd. Deze gisten zijn opportunisten en behoren dan oak 
tot de normale flora van het maagdarm·kanaal en leven daar onder normale 
omstandigheden in evenwicht met de cellen van de huid en slijmvliezen van de gastheer. 
Verstoring van deze balans als gevolg van bovengenoemde risicofactoren, kan leiden tot 
uitgroei van deze gisten hetgeen kan resulteren in oppervlakkige infecties van de 
slijmvliezen of in gedissemineerde infecties waarbij via het bloed vrijwel elk orgaan van 
het lichaam gernfecteerd kan raken. 
Oppervlakkige infecties zijn gemakkelijk herkenbaar en kunnen in het algemeen 
behandeld worden met lokale middelen, terwijl gedissemineerde infecties geen 
karakteristiek beeld tonen en altijd systemisch behandeld moeten worden. Het is dus van 
belang am deze vormen van infectie van elkaar te kunnen onderscheiden in verband met 
de toxiciteit van de huidige antifungale middelen die gebruikt worden bij systemische 
infecties. 
De diagnostiek van invasieve Candida infecties is erg moeilijk; het nemen van 
biopten is meestal niet mogelijk en bloedkweken zijn ondanks het gebruik van de 
gevoelige Iysiscentrifuge methode nog vaak negatief. Anderzijds is het aantonen van C. 
albicans in sputum, urine en feces geen bewijs voor invasieve candidiasis. De correcte 
diagnose is echter van groot belang voor de patient, gezien het vaak fatale verloop van 
invasieve infecties, met name wanneer er niet behandeld wordt. Men is dan ook steeds 
meer aangewezen op de uitslagen van serodiagnostisch onderzoek. De betrouwbaarheid 
van serologisch onderzoek laat echter te wensen over. Dit heeft te maken met: a, het 
commensale karakter van verschillende gistsoorten hetgeen kan leiden tot fout-positieve 
uitslagen en b, het niet optreden van een immuunrespons bij immuun gecompromiteerde 
patienten hetgeen nogal eens fout-negatieve uitslagen geeft. 
Het is bekend dat antilichamen gericht tegen de buitenkant van de gist, het 
celwand-mannan, algemeen voorkomen bij paW~nten met een invasieve candidiasis, 
patienten met een Candida kolonisatie of bij gezonde personen. Voor het aantonen van 
antilichamen gericht tegen Candida-soorten is gezocht naar antigenen die gerelateerd zijn 
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aan de invasieve varm van infectie. 
In ons onderzoek is gekeken naar de bruikbaarheid van antilichamen gericht tegen 
cytoplasmatische antigenen voor de diagnostiek van invasieve candidiasis (Hoofdstuk 2). 
Met behulp van de counterimmunoelectrophorese(CIE), een immunodiffusie techiek, zijn 
zowel de antilichamen gericht tegen cytoplasmatische antigenen [M(-)CIE] bepaald als ook 
tegen een ruw Candida extract [M( + )CIE] welke nog het celwand-mannan beva!. Beide 
antilichaam titers zijn bepaald in sera van immunocompetente patienten met een Candida 
kolonisatie of met een invasieve candidiasis. De specificiteit van de M(-)CIE (78.6%) was 
hoger in vergelijking met de specificiteit van de M( + )CIE (28.6%), hetgeen gepaard ging 
met een beperkt verlies in gevoeligheid van 80% voar de M( + )CIE naar 70% voor de M(-
)CIE. Het gebruik van cytoplasmatische antigenen ontdaan van mannan voor de detectie 
van antilichamen verbetert de serodiagnostiek van invasieve candidiasis in 
immunocompetente patienten. 
Het gebruik van cytoplasmatische antigenen werd verder uitgebouwd door gebruik 
te maken van een compleet gezuiverd immunodominant antigeen, het glycolytisch 
enolase enzym, voar de detectie van antilichamen in sera van immunocompetente en 
immunodeficiente patienten met invasieve candidiasis of een C. albicans kolonisatie 
(Hoofdstuk 3). Om eventueel verlies in gevoeligheid van de assay te beperken, werd 
gebruik gemaakt van een gevoelige antilichaam detectiemethode, namelijk de enzyme-
linked immunosorbent assay (ELISA). Desondanks bleek de enolase ELISA, bij 
immunocompetente patienten, een minder gevoelige diagnostische methode (50%) dan 
de M( + )CIE (80%). De goede specificiteit van de enolase ELISA (86%) ondersteunt de 
diagnose invasieve candidiasis in tegenstelling tot de M( + )CIE. Bij immunodeficiente 
patienten, met name leukemie patienten met een invasieve candidiasis heeft de enolase 
ELISA een beperkte waarde. Bij deze patienten konden namelijk geen anti-enolase 
antilichamen worden aangetoond. Voor hen is waarschijnlijk antigeen detectie of de anti-
mannan antilichaam detectie diagnostisch waardevoller. 
In een drietal immunodeficiente patienten met invasieve candidiasis werd de 
produktie van antilichamen gericht tegen cytoplasmatische antigenen en tegen een ruw 
Candida extract als ook de antigeen varming gedurende lange tijd bestudeerd (Hoofdstuk 
4). Bij deze immuun gecompromiteerde patienten bleek dat antilichamen gericht tegen 
het celwand-mannan en de detectie van antigenen een belangrijke rol spelen bij het 
stell en van de diagnose invasieve candidiasis. De toename in de concentratie van anti R 
mannan antilichamen is bruikbaar als een vroege indicatorvoor een actief infectie-proces. 
Deze waarneming werd bevestigd bij bestudering van een grotere groep 
immunodeficiente patienten met invasieve candidiasis (Hoofdstuk 4). In deze studie bleek 
verder dat de antigeen-detectie niet correleerde met het infectie proces en daardoor niet 
automatisch als optimale serologische test bij immuun gecompromiteerde beschouwd 
mag worden. Het gebruik van serologische testen is dus afhankelijk van het onderliggend 
lijden van de patient en uitslagen van serologische testen bij bijvoorbeeld leukemie of 
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chirurgische patienten eisen dan ook een andere interpretatie. 
Moleculair biologische technieken zijn waardevol gebleken bij het aantonen van 
verschillende bacteriele infecties en zouden tevens de diagnostiek van invasive Candida 
infecties kunnen verbeteren. Deze techniek biedt namelijk de mogelijkheid om kleine 
hoeveelheden cellen in klinisch materiaal aan te tonen. De methode is vaak sneller dan 
bloedkweken, omdat deze langdurig moeten worden ge'(ncubeerd voordat zij als negatief 
kunnen worden beschouwd. In dit onderzoek is gebruik gemaakt van de enzymatische 
amplificatie van het gen coderend voor het small subunit ribosomale 185 RNA met 
behulp van de polymerase chain reaction (PCR). Het geamplificeerde produkt is niet 
specifiek voor C. albicans maar is geconserveerd over verschillende eukaryoten. Met 
gebruikmaking van species-specifieke probes en hybridisatie technieken kon het 
amplificaat van 10 tot 15 C. albicans cellen in 100/11 bloed specifiek worden aangetoond 
(Hoofdstuk 6). 
De diagnostische waarde van de PCR is onderzocht in een muizenmodel met een 
maagdarm~kolonisatie en in een muizenmodel met invasieve candidiasis. Negatieve 
hybridisatiesignalen en negatieve bloedkweekresultaten werden verkregen van bloed 
afgenomen bij muizen met een maagdarm-kolonisatie met C. albicans. In muizen met 
een invasieve candidiasis bleek de PCR vaker positief dan de bloedkweek. 
Tweeenzeventig uur na het aanbrengen van de infectie bleek 100% van de muizen een 
positieve PCR reactie te hebben terwijl slechts 67% positieve bloedkweken had 
(Hoofdstuk 6). Daarnaast bleek de intensiteit van het hybridisatie-signaal toe te nemen 
naarmate het infectie proces vorderde. Het hybridisatie-signaal leek gecorreleerd te zijn 
aan de intensiteit van de Candida infectie. De PCR-techniek zou dus gebruikt kunnen 
worden in het vervolgen van de Candida infectie tijdens bijvoorbeeld antifungale 
behandeling. 
Dit prognostische aspect van de PCR werd bestudeerd in muizen met een lethale 
C. albicans infectie die effectief of partieel behandeld werden met verschillende 
concentraties liposomaal Amphotericine B (Ambisome®) (1, 7 en 14 mg AmB/kg). Na 4 
dagelijkse behandelingen met 1 mg AmB/kg groeide de Candida infectie bij deze muizen 
weer uit terwijl 4 behandelingen met 7 of 14 mg AmB/kg steriele muizen op basis van 
kweekresultaten gaf. Het hybridisatie-signaal van de PCR uitgevoerd op bloed bleek te 
correleren met de mate van infectie. Dit was niet het geval met de bloedkweken die 
meestal negatief waren. Dit betekent dat de PCR gebruikt kan worden voor het vervolgen 
van een Candida infectie tijdens antifungale behandeling. Voar het vaststellen van de 
bruikbaarheid van de PCR als diagnostische en prognostische test is verder onderzoek bij 
patienten noodzakelijk. 
Naast de diagnostische waarde van antilichamen gericht tegen verschillende 
antigenen van C. albicans, staat hun rol in het afweermechanisme tegen een invasieve 
Candida infectie al geruime tijd in de belangstelling. Het be lang van antilichamen in de 
afweer tegen candidiasis werd bestudeerd in een muizenmodel, waarbij immunotransfer 
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werd uitgevoerd met verschillende antilichamen gericht tegen C. albicans. Deze 
antilichamen zijn gericht tegen het immunodominante enolase, tegen een ruw C. albicans 
extract en tegen het celwand-mannan (Hoofdstuk 5). Het anti-enolase antiserum (lMS) en 
het anti-mann an antiserum (MAB 18Cll), beide opgewekt in muizen en het anti-ruw C. 
albicans antiserum opgewekt in konijnen (IRS), werden herhaaldelijk ingespoten in 
muizen met een dodelijk verlopende invasieve Candida infectie. Het IMS en IRS maar 
niet het MAB 18Cll, gaven een gedeeltelijke bescherming. Dit beschermend effect kon 
niet worden verklaard door een verbeterde opruiming van de gistcellen in de 
verschillende organen, of door een andere verdeling over de verschillende organen, in 
een vroeg stadium van het infectieproces. Eveneens kon er geen verschil worden 
aangetoond in de mate waarin de met verschillende immuunsera en normaal sera 
geopsoniseerde C. albicans cellen werden gefagocyteerd door peritoneaal macrofagen in 
in vitro fagocytose experimenten. Een verklaring voor het beschermend effect van anti-
enolase antilichamen kan nag niet gegeven worden verder onderzoek naar de 
werkingsmechanisme zal nodig zijn. 
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